Nitrogen-containing heteroaryl compound, preparation method thereof and application of nitrogen-containing heteroaryl compound in medicine
By developing nitrogen-containing heteroaryl compounds of general formula (I) as MK2 inhibitors, the problems of drug resistance response and feedback activation in clinical applications of existing p38 MAPK inhibitors have been solved, and a lasting inflammatory inhibition effect has been achieved.
Patent Information
- Application Number
- CN202410544322.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-06
- Filing Date
- 2024-05-06
- Publication Date
- 2024-11-08
AI Technical Summary
The existing p38 MAPK inhibitors have rapid drug resistance responses in clinical applications, and the activation of feedback mechanisms on inflammatory cytokines leads to unstable therapeutic effects, making it difficult to provide lasting inflammatory inhibition.
Develop a nitrogen-containing heteroaryl compound of general formula (I) as an MK2 inhibitor, which binds to MK2 through a specific structure to inhibit its phosphorylation activity, thereby regulating the translation and stability of inflammatory cytokines, providing lasting anti-inflammatory Treatment effect.
Effectively inhibit the activity of MK2, reduce the production of inflammatory cytokines, provide long-lasting anti-inflammatory therapeutic effects, avoid feedback activation problems of p38 signaling pathway, and improve the stability and safety of treatment.
Smart Images

Figure CN118908960A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure belongs to the field of medicine, and relates to a nitrogen-containing heteroaryl compound, a preparation method thereof, and its application in medicine. In particular, the present disclosure relates to a nitrogen-containing heteroaryl compound represented by general formula (I), a preparation method thereof, and a pharmaceutical composition containing the compound, as well as its use as an MK2 inhibitor and its use for treating and / or preventing autoimmune diseases, chronic or acute inflammatory diseases, and autoinflammatory diseases. Background Art
[0002] Inflammatory cytokines play an important role in the pathogenesis of autoimmune diseases. Biologics that neutralize key inflammatory cytokines, such as anti-TNFα antibodies, have been shown to be useful in treating inflammatory diseases such as psoriasis, Crohn's disease (CD), rheumatoid arthritis (RA), and spondyloarthritis. Biologics are currently administered parenterally, and as the duration of medication increases, there is a risk of reduced efficacy. Therefore, new oral therapies for the treatment of inflammatory diseases need to be developed.
[0003] p38 MAPK was identified as a key regulator of inflammatory cytokine biosynthesis in 1994, and numerous R&D institutions have conducted work on small molecule kinase inhibitors targeting p38. Most p38 kinase inhibitors have shown efficacy in animal disease models, but have not been further developed clinically due to insufficient safety windows. Three p38 compounds that have entered Phase II clinical trials were conducted in patients with RA or CD. In the initial stages of the experiments, a decrease in disease scores or biomarkers of inflammation was observed, and then continued administration led to rapid drug resistance. Analysis showed that this phenomenon was mainly due to the inhibition of p38, which, in addition to inhibiting inflammation, also activates the feedback mechanism of p38. Given the important role of the p38 signaling pathway in cytokine biosynthesis, targeting molecules in the upstream or downstream pathways of p38 may circumvent regulatory feedback and provide the lasting therapeutic benefits required for sustained inhibition of inflammatory cytokines.
[0004] MAPK-activated protein kinase 2 (MK2) is a direct downstream substrate of p38 and mediates the inflammatory process by increasing the translation and stability of proinflammatory cytokine mRNAs, including IL-6 and TNFa. Tristetraprolin (TTP) is a zinc finger protein that can bind to cytokine mRNAs with the same adenylate-uridylate-rich element (ARE) in the 30 untranslated regions, making these mRNAs unstable and inhibiting the protein translation of these cytokines, while human antigen R (HuR) plays the opposite role and stimulates translation. Activated MK2 phosphorylates TTP, resulting in TTP being replaced by HuR, thereby regulating cytokine production. In the MK2 knockout mouse model, mice grow normally, resist LPS-induced endotoxin shock, and show reduced levels of TNFα, IL-6, and interferon γ; in addition, knocking out MK2 in many inflammatory disease models, including the collagen-induced arthritis model, can alleviate the occurrence of these diseases or the level of inflammation. Therefore, MK2 is a potential target for the treatment of inflammation. Although there is no evidence that MK2 is in a complex feedback pathway like p38, its activation does activate signaling feedback that limits inflammation at the level of TTP-regulated translation or mRNA stability.
[0005] The patent applications for MK2 inhibitors that have been disclosed include WO2023283338A1, WO2022212489A1, WO2014197846A1, WO2013086208A1 and WO2012078684A1. Summary of the invention
[0006] The purpose of the present disclosure is to provide a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof:
[0007]
[0008] Ring A is a heteroaryl group;
[0009] Ring B is phenyl or monocyclic heteroaryl;
[0010] Ring C is selected from cycloalkyl, heterocyclyl, aryl and heteroaryl;
[0011] X is N or CR 5 ;
[0012] Y is N or CR 6 ;
[0013] Z is N or CR 7 ;
[0014] R 0is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, a hydroxyalkyl group, an alkoxyalkyl group, an aminoalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group;
[0015] Each R 1 , R 2 and R 3 are the same or different and are each independently selected from a deuterium atom, a halogen, an alkyl, a haloalkyl, a deuterated alkyl, a hydroxyalkyl, an alkoxyalkyl, an aminoalkyl, an alkoxy, a haloalkoxy, a deuterated alkoxy, an alkenyl, an alkynyl, a cyano group, a nitro group, a hydroxyl group, an amino group, an oxo group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, a heteroarylalkyl group, a -(CH2) t OR 8 、-(CH2) t NR 9 R 10 、-C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-OC(O)OR 8 、-C(O)NR 9 R 10 、-OC(O)NR 9 R 10 、-S(O) v R 8 、-S(O) v NR 9 R 10 、-NR 11 C(O)NR 9 R 10 、-NR 11 C(O)R 8 and-NR 11 C(O)OR 8 wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R A replace;
[0016] R 4 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, a hydroxyalkyl group, an alkoxyalkyl group, an aminoalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group;
[0017] R 5 , R 6 and R 7are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, a hydroxyalkyl group, an alkoxyalkyl group, an aminoalkyl group, an alkoxy group, a haloalkoxy group, a deuterated alkoxy group, an alkenyl group, an alkynyl group, a cyano group, a nitro group, a hydroxyl group, an amino group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, a heteroarylalkyl group, a -(CH2) t OR 8 、-(CH2) t NR 9 R 10 、-C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-OC(O)OR 8 、-C(O)NR 9 R 10 、-OC(O)NR 9 R 10 、-S(O) v R 8 、-S(O) v NR 9 R 10 、-NR 11 C(O)NR 9 R 10 、-NR 11 C(O)R 8 and-NR 11 C(O)OR 8 wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R A replace;
[0018] R A are the same or different at each occurrence and are each independently selected from a deuterium atom, a halogen, an alkyl, a haloalkyl, a deuterated alkyl, a hydroxyalkyl, an alkoxyalkyl, an aminoalkyl, an alkoxy, a haloalkoxy, a deuterated alkoxy, an alkenyl, an alkynyl, a cyano group, a nitro group, a hydroxyl group, an amino, a cycloalkyl, a heterocyclyl, a cycloalkylalkyl, a heterocyclylalkyl, an aryl, a heteroaryl, an arylalkyl, a heteroarylalkyl, an oxo group, a -(CH2) t OR 12 、-(CH2) t NR 13 R 14 、-C(O)R 12 、-C(O)OR 12 and -C(O)NR 13 R 14 ;
[0019] R 8 and R 12 are the same or different at each occurrence and are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, deuterated alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl; wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl is independently optionally replaced by one or more R B replace;
[0020] R 9 , R 10 , R 11 , R 13 and R 14 are the same or different at each occurrence and are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, deuterated alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl; wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl is independently optionally replaced by one or more R B replace;
[0021] or R 9 and R 10 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R B Replace; or R 13 and R 14 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R B replace;
[0022] R B are the same or different at each occurrence and are each independently selected from the group consisting of a deuterium atom, a halogen, an alkyl, a haloalkyl, a deuterated alkyl, a hydroxyalkyl, an alkoxyalkyl, an aminoalkyl, an alkoxy, a haloalkoxy, a deuterated alkoxy, an alkenyl, an alkynyl, a cyano group, a nitro group, a hydroxyl group, an amino group, -NHCH3, -N(CH3)2, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, a heterocyclylalkyl group, a cycloalkyloxy group, a heterocyclyloxy group, an aryl group, a heteroaryl group, an arylalkyl group, a heteroarylalkyl group, an aryloxy group, a heteroaryloxy group, and an oxo group;
[0023] m is 0, 1, 2, 3 or 4;
[0024] n is 0, 1, 2, 3, 4 or 5;
[0025] p is 0, 1, 2, 3, 4 or 5;
[0026] t is 0, 1, 2, 3 or 4; and
[0027] v is 0, 1, or 2.
[0028] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R 0 A hydrogen atom or C 1-6 alkyl; in some embodiments, R 0 is a hydrogen atom; in some embodiments, R 0 C 1-6 alkyl; in some embodiments, R 0 is methyl; in some embodiments, R 0 A hydrogen atom or a methyl group.
[0029] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R 4 A hydrogen atom or C 1-6 alkyl; in some embodiments, R 4 is a hydrogen atom; in some embodiments, R 4 C 1-6 alkyl; in some embodiments, R 4 is methyl; in some embodiments, R 4 A hydrogen atom or a methyl group.
[0030] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R 5 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R 5 is a hydrogen atom or a halogen; in some embodiments, R 5 A hydrogen atom.
[0031] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein X is N; in some embodiments, X is CR 5 ; R 5 As defined in Formula (I); in some embodiments, X is CH; in some embodiments, X is N or CH.
[0032] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof:
[0033]
[0034] in:
[0035] Ring A, Ring B, Ring C, Y, Z, R 1 , R 2 , R 3 , m, n and p are as defined in the general formula (I).
[0036] In some embodiments of the present disclosure, the compound represented by the general formula (I) or general formula (II) or a pharmaceutically acceptable salt thereof, wherein ring A is a 5- or 6-membered heteroaryl group; in some embodiments, ring A is a 6-membered heteroaryl group; in some embodiments, ring A is a pyridyl or pyrimidyl group; in some embodiments, ring A is a pyridyl group; in some embodiments, ring A is a pyrimidyl group.
[0037] In some embodiments of the present disclosure, the compound represented by the general formula (I) or the general formula (II) or a pharmaceutically acceptable salt thereof, wherein Selected from R 1 and m are as defined in Formula (I); in some embodiments, for R 1 and m are as defined in Formula (I); in some embodiments, for R 1a , R 1b , R 1c and R 1d are the same or different and are each independently a hydrogen atom or R 1 ; R 1 As defined in formula (I); in some embodiments, for R 1a and R 1c are the same or different and are each independently a hydrogen atom or R 1 ; R 1 As defined in formula (I); in some embodiments, Selected from In some embodiments, for
[0038] In some embodiments of the present disclosure, the compound represented by the general formula (I) or (II) or a pharmaceutically acceptable salt thereof, wherein ring B is phenyl or a 5- or 6-membered heteroaryl; in some embodiments, ring B is phenyl or a 6-membered heteroaryl; in some embodiments, ring B is phenyl; in some embodiments, ring B is a 6-membered heteroaryl; in some embodiments, ring B is pyridyl; in some embodiments, ring B is phenyl or pyridyl.
[0039] In some embodiments of the present disclosure, the compound represented by the general formula (I) or the general formula (II) or a pharmaceutically acceptable salt thereof, wherein for Q is N or CR 2d ; R 2a , R 2b , R 2c and R 2d are the same or different and are each independently a hydrogen atom or R 2 ; R 2 As defined in formula (I); in some embodiments, for Q is N or CH; R 2a is a hydrogen atom or R 2 ; R 2b is a hydrogen atom or R 2 ; R 2 As defined in formula (I); in some embodiments, for Q is N or CH; R 2b is a hydrogen atom or R 2 ; R 2 As defined in formula (I); in some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, Selected from *End is connected to ring C.
[0040] In some embodiments of the present disclosure, the compound represented by the general formula (I) or the general formula (II) or a pharmaceutically acceptable salt thereof, wherein ring C is a 5- or 6-membered heteroaryl group; in some embodiments, ring C is a 6-membered heteroaryl group; in some embodiments, ring C is a pyrimidinyl or pyridone group; in some embodiments, ring C is a pyridinyl or pyrimidinyl group; in some embodiments, ring C is a pyrimidinyl group; in some embodiments, ring C is a pyridone group; in some embodiments, ring C is a pyridinyl group; in some embodiments, ring C is Connected to ring B.
[0041] In some embodiments of the present disclosure, the compound represented by the general formula (I) or the general formula (II) or a pharmaceutically acceptable salt thereof, wherein for E is N or CR 3d ; R 3a , R 3b, R 3c and R 3d are the same or different and are each independently a hydrogen atom or R 3 ; R 3 As defined in formula (I); in some embodiments, for R 3a , R 3b , R 3c and R 3d are the same or different and are each independently a hydrogen atom or R 3 ; R 3 As defined in formula (I); in some embodiments, for R 3a , R 3b and R 3c are the same or different and are each independently a hydrogen atom or R 3 ; R 3 As defined in formula (I); in some embodiments, for R 3a and R 3c are the same or different and are each independently a hydrogen atom or R 3 ; R 3 As defined in formula (I); in some embodiments, for R 3a is a hydrogen atom or R 3 ; R 3 As defined in formula (I); in some embodiments, for R 3a is a hydrogen atom or R 3 ; R 3 As defined in formula (I); in some embodiments, Selected from In some embodiments, for
[0042] In some embodiments of the present disclosure, the compound represented by the general formula (I) or the general formula (II) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof,
[0043]
[0044] in:
[0045] Q is N or CR 2d ;
[0046] E is N or CR 3d ;
[0047] R 1a , R 1b , R 1c and R 1d are the same or different and are each independently a hydrogen atom or R 1 ;
[0048] R 2a , R 2b , R 2c and R 2d are the same or different and are each independently a hydrogen atom or R 2 ;
[0049] R 3a , R 3b , R 3c and R 3d are the same or different and are each independently a hydrogen atom or R 3 ;
[0050] Y, Z, R 1 , R 2 and R 3 As defined in general formula (I).
[0051] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein each R 1 are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 alkoxy, cyano, and 3- to 6-membered cycloalkyl; in some embodiments, each R 1 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, each R 1 are the same or different and are each independently halogen; in some embodiments, each R 1 are the same or different and are each independently F or Cl; in some embodiments, R 1 is F; in some embodiments, R 1 For Cl.
[0052] In some embodiments of the present disclosure, the compound represented by the general formula (I) or (II) or a pharmaceutically acceptable salt thereof, wherein m is 0, 1 or 2; in some embodiments, m is 1 or 2; in some embodiments, m is 2; in some embodiments, m is 1.
[0053] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein each R 2 are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 alkoxy, cyano, and 3- to 6-membered cycloalkyl; in some embodiments, each R 2 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, each R 2 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 alkoxy; in some embodiments, each R 2 are the same or different and are each independently halogen or C 1-6 alkyl; in some embodiments, each R 2 are the same or different and are each independently halogen; in some embodiments, each R 2 The same or different, and each independently is C 1-6 alkyl; in some embodiments, each R 2 are the same or different and are each independently selected from methyl, F and methoxy; in some embodiments, R 2 It is methyl.
[0054] In some embodiments of the present disclosure, the compound represented by the general formula (I) or general formula (II) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1 or 2; in some embodiments, n is 1 or 2; in some embodiments, n is 0 or 1; in some embodiments, n is 1; in some embodiments, n is 2.
[0055] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein each R 3 are the same or different and are each independently selected from halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6alkyl; in some embodiments, each R 3 are the same or different and are each independently selected from halogen, cyano, C 1-6 Alkyl and C 1-6 hydroxyalkyl; in some embodiments, each R 3 The same or different, and each independently selected from C 1-6 Alkyl, C 2-6 alkenyl and 3 to 8 membered cycloalkyl; said C 1-6 Alkyl, C 2-6 The alkenyl group and the 3 to 8 membered cycloalkyl group are each independently optionally substituted by one or more R A Replacement; R A As defined in Formula (I); in some embodiments, each R 3 The same or different, and each independently selected from C 1-6 Alkyl, C 2-6 alkenyl and 3 to 8 membered cycloalkyl; said C 1-6 Alkyl, C 2-6 The alkenyl group and the 3 to 8 membered cycloalkyl group are each independently optionally selected from C 1-6 alkyl, hydroxyl and 3 to 6-membered cycloalkyl; in some embodiments, each R 3 The same or different, and each independently is C 1-6 hydroxyalkyl; in some embodiments, each R 3 The same or different, and each independently selected from In some embodiments, each R 3 are the same or different and are each independently selected from methyl, cyano, F and In some embodiments, R 3 for
[0056] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein R A Selected from C 1-6 alkyl, hydroxyl and 3 to 6 membered cycloalkyl; in some embodiments, R A is hydroxy or 3 to 6-membered cycloalkyl; in some embodiments, R A is hydroxy or cyclopropyl; in some embodiments, R A It is hydroxyl.
[0057] In some embodiments of the present disclosure, the compound represented by the general formula (I) or (II) or a pharmaceutically acceptable salt thereof, wherein p is 1 or 2; in some embodiments, p is 1; in some embodiments, p is 2.
[0058] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 1a , R 1b , R 1c and R 1d are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 alkoxy, cyano, and 3- to 6-membered cycloalkyl; in some embodiments, R 1a , R 1b , R 1c and R 1d are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R 1a , R 1b , R 1c and R 1d are the same or different and are each independently a hydrogen atom or a halogen; in some embodiments, R 1a , R 1b , R 1c and R 1d are the same or different and are each independently selected from hydrogen, F and Cl; in some embodiments, R 1a , R 1b , R 1c and R 1d are the same or different and are each independently a hydrogen atom or F; in some embodiments, R 1a is halogen; R 1b is a hydrogen atom; R 1c is a hydrogen atom or a halogen; R 1d is a hydrogen atom; in some embodiments, R 1a is halogen; R 1b is a hydrogen atom; R 1c is halogen; R 1d is a hydrogen atom; in some embodiments, R 1a is F or Cl; R 1b is a hydrogen atom; R 1c is a hydrogen atom, F or Cl; R 1d is a hydrogen atom; in some embodiments, R 1a F; R 1b is a hydrogen atom; R 1c F; R 1d A hydrogen atom.
[0059] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 2a , R 2b and R 2c are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 alkoxy, cyano, and 3- to 6-membered cycloalkyl; in some embodiments, R 2a , R 2b and R 2c are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R 2a , R 2b and R 2c are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Alkoxy; in some embodiments, R 2a , R 2b and R 2c are the same or different and are each independently selected from hydrogen atoms, halogens and C 1-6 alkyl; in some embodiments, R 2a , R 2b and R 2c are the same or different and are each independently a hydrogen atom or a halogen; in some embodiments, R 2a , R 2b and R 2c are the same or different and are each independently a hydrogen atom or a C 1-6 alkyl; in some embodiments, R 2a , R 2b and R 2c are the same or different and are each independently a hydrogen atom or a methyl group; in some embodiments, R 2b Selected from hydrogen atoms, halogens and C 1-6 Alkyl; R 2a and R 2c is a hydrogen atom; in some embodiments, R 2b A hydrogen atom or C 1-6 Alkyl; R 2a and R 2c is a hydrogen atom; in some embodiments, R 2b is halogen; R 2a and R 2c is a hydrogen atom; in some embodiments, R 2b Cl; R2a and R 2c is a hydrogen atom; in some embodiments, R 2b C 1-6 Alkyl; R 2a and R 2c is a hydrogen atom; in some embodiments, R 2b is methyl; R 2a and R 2c is a hydrogen atom; in some embodiments, R 2a , R 2b and R 2c A hydrogen atom.
[0060] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 2a is a hydrogen atom or a halogen; in some embodiments, R 2a is a hydrogen atom; in some embodiments, R 2a is a hydrogen atom or F.
[0061] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 2b Selected from halogen, C 1-6 Alkyl and C 1-6 Alkoxy; in some embodiments, R 2b C 1-6 alkyl; in some embodiments, R 2b is F, methyl and methoxy; in some embodiments, R 2b It is methyl.
[0062] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 2c A hydrogen atom.
[0063] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 2d Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 alkoxy, cyano, and 3- to 6-membered cycloalkyl; in some embodiments, R 2d Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R 2dis a hydrogen atom or a halogen; in some embodiments, R 2d A hydrogen atom or C 1-6 alkyl; in some embodiments, R 2d A hydrogen atom.
[0064] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein Q is N; in some embodiments, Q is CR 2d ; R 2d As defined in formula (III); in some embodiments, Q is N or CH; in some embodiments, Q is CH.
[0065] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein Q is N or CH; and / or R 2b Selected from halogen, C 1-6 Alkyl and C 1-6 Alkoxy; and / or R 2a is a hydrogen atom or a halogen; and / or R 2c is a hydrogen atom; in some embodiments Q is N or CH; and / or R 2b C 1-6 Alkyl; R 2a and R 2c is a hydrogen atom; in some embodiments, Q is CH; and / or R 2b C 1-6 Alkyl; R 2a and R 2c is a hydrogen atom; in some embodiments, Q is CH; and / or R 2b is methyl; R 2a and R 2c A hydrogen atom.
[0066] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 3a , R 3b and R 3c are the same or different and are each independently selected from hydrogen, halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6 alkyl; in some embodiments, R 3a , R 3b and R 3c are the same or different and are each independently selected from hydrogen, halogen, cyano, C 1-6 Alkyl and C1-6 Hydroxyalkyl; in some embodiments, R 3a , R 3b and R 3c are the same or different and are each independently a hydrogen atom or a C 1-6 Hydroxyalkyl; in some embodiments, R 3a , R 3b and R 3c are the same or different and are each independently selected from hydrogen, methyl, cyano, F and In some embodiments, R 3a , R 3b and R 3c are the same or different and are each independently a hydrogen atom or In some embodiments, R 3a C 1-6 Hydroxyalkyl; R 3b is a hydrogen atom; R 3c Selected from hydrogen atoms, halogens, cyano groups and C 1-6 alkyl; in some embodiments, R 3a C 1-6 Hydroxyalkyl; R 3b and R 3c is a hydrogen atom; in some embodiments, R 3a for R 3b is a hydrogen atom; R 3c is selected from hydrogen, methyl, cyano and F; in some embodiments, R 3a for R 3b and R 3c A hydrogen atom.
[0067] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 3a Selected from C 1-6 Alkyl, C 2-6 alkenyl and 3 to 8 membered cycloalkyl; said C 1-6 Alkyl, C 2-6 The alkenyl group and the 3 to 8 membered cycloalkyl group are each independently optionally substituted by one or more R A Replacement; R A As defined in Formula (I); in some embodiments, R 3a Selected from C 1-6 Alkyl, C 2-6 alkenyl and 3 to 8 membered cycloalkyl; said C 1-6 Alkyl, C 2-6 The alkenyl group and the 3 to 8 membered cycloalkyl group are each independently optionally selected from C 1-6alkyl, hydroxyl and 3 to 6-membered cycloalkyl; in some embodiments, R 3a C 1-6 Hydroxyalkyl; in some embodiments, R 3a Selected from In some embodiments, R 3a for
[0068] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 3b Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R 3b is a hydrogen atom or a halogen; in some embodiments, R 3b A hydrogen atom or C 1-6 alkyl; in some embodiments, R 3b A hydrogen atom.
[0069] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 3c Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R 3c is a hydrogen atom or a halogen; in some embodiments, R 3c A hydrogen atom or C 1-6 alkyl; in some embodiments, R 3c A hydrogen atom.
[0070] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 3d Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R 3d is a hydrogen atom or a halogen; in some embodiments, R 3d A hydrogen atom or C 1-6 alkyl; in some embodiments, R 3d A hydrogen atom.
[0071] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein E is N; in some embodiments, E is CR 3d ; R 3dAs defined in formula (III); in some embodiments, E is N or CH; in some embodiments, E is CH.
[0072] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein E is N; and / or R 3a Selected from C 1-6 Alkyl, C 2-6 alkenyl and 3 to 8 membered cycloalkyl; said C 1-6 Alkyl, C 2-6 The alkenyl group and the 3 to 8 membered cycloalkyl group are each independently optionally selected from C 1-6 alkyl, hydroxyl and 3 to 6-membered cycloalkyl; and / or R 3b is a hydrogen atom; and / or R 3c is a hydrogen atom; in some embodiments, E is N; and / or R 3a C 1-6 Hydroxyalkyl; R 3b and R 3c is a hydrogen atom; in some embodiments, E is N; and / or R 3a for R 3b and R 3c A hydrogen atom.
[0073] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 6 and R 7 are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R 6 and R 7 are the same or different and are each independently a hydrogen atom or a halogen; in some embodiments, R 6 and R 7 are the same or different and are each independently a hydrogen atom or a C 1-6 alkyl; in some embodiments, R 6 and R 7 are the same or different and are each independently a hydrogen atom or a methyl group; in some embodiments, R 6 is a hydrogen atom, R 7 A hydrogen atom or C 1-6 alkyl; in some embodiments, R 6 and R 7 is a hydrogen atom; in some embodiments, R 6 is a hydrogen atom; in some embodiments, R 7 A hydrogen atom.
[0074] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein Y is N, Z is CR 7 ; or Y is CR 6 , Z is N; or, Y is CR 6 , Z is CR 7 ; R 6 and R 7 As defined in general formula (I); in some embodiments, Y is N, Z is CR 7 ; or Y is CR 6 , Z is N; R 6 and R 7 As defined in general formula (I); in some embodiments, Y is N, Z is CR 7 ; R 7 As defined in formula (I); in some embodiments, Y is CR 6 , Z is N; R 6 As defined in formula (I); in some embodiments, Y is CR 6 , Z is CR 7 ; R 6 and R 7 As defined in formula (I); in some embodiments, Y is N and Z is CH; or Y is CH and Z is N; in some embodiments, Y is N and Z is CH; in some embodiments, Y is CH and Z is N.
[0075] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein Selected from R 6 and R 7 As defined in general formula (I); in some embodiments, for R 6 and R 7 As defined in general formula (I); in some embodiments, for R 7 As defined in general formula (I); in some embodiments, Selected from In some embodiments, for In some embodiments, for *End and NR 0 connect.
[0076] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein Selected from In some embodiments, Selected from In some embodiments, for *The end is connected to NH.
[0077] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is a 6-membered heteroaryl; ring B is a phenyl group or a 6-membered heteroaryl group; ring C is a 6-membered heteroaryl group; X is N; Y is N, and Z is CH; or Y is CH, and Z is N; R 0 is a hydrogen atom; each R 1 are the same or different and are each independently halogen; m is 2; R 2 C 1-6 Alkyl; n is 1; R 3 C 1-6 Hydroxyalkyl; p is 1; R 4 A hydrogen atom.
[0078] In some embodiments of the present disclosure, the compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof, wherein ring A is pyridyl; ring B is phenyl; ring C is a 6-membered heteroaryl; Y is N, and Z is CH; or Y is CH, and Z is N; each R 1 are the same or different and are each independently halogen; m is 2; R 2 C 1-6 Alkyl; n is 1; R 3 C 1-6 Hydroxyalkyl; p is 1.
[0079] In some embodiments of the present disclosure, the compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof, wherein Y is N, Z is CH; or Y is CH, Z is N; Q is N or CH; E is N or CH; R 1a is halogen; R 1b is a hydrogen atom; R 1c is halogen; R 1d is a hydrogen atom; R 2b C 1-6 Alkyl; R 2a and R 2c is a hydrogen atom; R 3a C 1-6 Hydroxyalkyl; R 3b and R 3c A hydrogen atom.
[0080] In some embodiments of the present disclosure, the compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof, wherein Y is N, Z is CH; Q is CH; E is N; R 1a is halogen; R 1b is a hydrogen atom; R 1c is halogen; R 1d is a hydrogen atom; R 2b C 1-6 Alkyl; R 2a and R 2c is a hydrogen atom; R 3a C 1-6 Hydroxyalkyl; R 3b and R 3c A hydrogen atom.
[0081] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is pyridyl; ring B is phenyl or pyridyl; ring C is pyrimidyl or pyridone; Y is N, and Z is CR 7 ; or Y is CR 6 , Z is N; or, Y is CR 6 , Z is CR 7 ; R 6 and R 7 are the same or different and are each independently a hydrogen atom or a C 1-6 Alkyl; R 0 is a hydrogen atom; each R 1 are the same or different and are each independently halogen; m is 1 or 2; each R 2 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Alkoxy; n is 1 or 2; R 3 Selected from C 1-6 Alkyl, C 2-6 alkenyl and 3 to 8 membered cycloalkyl; said C 1-6 Alkyl, C 2-6 The alkenyl group and the 3 to 8 membered cycloalkyl group are each independently optionally selected from C 1-6 substituted with one or more substituents selected from alkyl, hydroxyl and 3- to 6-membered cycloalkyl; p is 1; R 4 A hydrogen atom.
[0082] In some embodiments of the present disclosure, the compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof, wherein Y is N, Z is CR 7 ; or Y is CR 6 , Z is N; or, Y is CR 6 , Z is CR 7 ; R 6 and R 7are the same or different and are each independently a hydrogen atom or a C 1-6 Alkyl; R 1a is halogen; R 1b is a hydrogen atom; R 1c is a hydrogen atom or a halogen; R 1d is a hydrogen atom; Q is N or CH; R 2b Selected from halogen, C 1-6 Alkyl and C 1-6 Alkoxy; R 2a is a hydrogen atom or a halogen; R 2c is a hydrogen atom; R 3a Selected from C 1-6 Alkyl, C 2-6 alkenyl and 3 to 8 membered cycloalkyl; said C 1-6 Alkyl, C 2-6 The alkenyl group and the 3 to 8 membered cycloalkyl group are each independently optionally selected from C 1-6 is substituted with one or more substituents selected from alkyl, hydroxy and 3- to 6-membered cycloalkyl; R 3b is a hydrogen atom; R 3c is a hydrogen atom; E is N.
[0083] Table A Typical compounds of the present disclosure include, but are not limited to:
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091] Another aspect of the present disclosure relates to a compound represented by general formula (IA) or a salt thereof:
[0092]
[0093] in:
[0094] PG is an amino protecting group; preferably, PG is SEM or THP;
[0095] Ring A, Ring B, Ring C, X, Y, Z, R 0 , R 1 , R 2 , R 3, m, n and p are as defined in the general formula (I).
[0096] Another aspect of the present disclosure relates to a compound represented by general formula (IIA) or a salt thereof:
[0097]
[0098] in:
[0099] PG is an amino protecting group; preferably, PG is SEM or THP;
[0100] Ring A, Ring B, Ring C, Y, Z, R 1 , R 2 , R 3 , m, n and p are as defined in the general formula (II).
[0101] Another aspect of the present disclosure relates to a compound represented by general formula (IIIA) or a salt thereof:
[0102]
[0103] in:
[0104] PG is an amino protecting group; preferably, PG is SEM or THP;
[0105] Y, Z, R 1a , R 1b , R 1c , R 1d , R 2a , R 2b , R 2c , R 3a , R 3b , R 3c , Q and E are as defined in the general formula (III).
[0106] Table B Typical intermediate compounds disclosed herein include but are not limited to:
[0107]
[0108]
[0109]
[0110]
[0111] Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising:
[0112]
[0113] Removing the protecting group from the compound represented by the general formula (IA) or its salt to obtain the compound represented by the general formula (I) or its pharmaceutically acceptable salt;
[0114] in:
[0115] PG is an amino protecting group; preferably, PG is SEM or THP;
[0116] R 4 is a hydrogen atom;
[0117] Ring A, Ring B, Ring C, X, Y, Z, R 0 , R 1 , R 2 , R 3 , m, n and p are as defined in the general formula (I).
[0118] Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising:
[0119]
[0120] Removing the protecting group from the compound represented by the general formula (IIA) or a salt thereof to obtain the compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof;
[0121] in:
[0122] PG is an amino protecting group; preferably, PG is SEM or THP;
[0123] Ring A, Ring B, Ring C, Y, Z, R 1 , R 2 , R 3 , m, n and p are as defined in the general formula (II).
[0124] Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof, the method comprising:
[0125]
[0126] Removing the protecting group from the compound represented by the general formula (IIIA) or a salt thereof to obtain the compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof;
[0127] in:
[0128] PG is an amino protecting group; preferably, PG is SEM or THP;
[0129] Y, Z, R 1a , R 1b , R 1c , R 1d , R2a , R 2b , R 2c , R 3a , R 3b , R 3c , Q and E are as defined in the general formula (III).
[0130] Another aspect of the present disclosure relates to a pharmaceutical composition, which contains a compound of the present disclosure represented by general formula (I), general formula (II), general formula (III) and Table A or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
[0131] The present disclosure further relates to the use of compounds represented by formula (I), formula (II), formula (III) and Table A or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising the same, in the preparation of MK2 inhibitors.
[0132] The present disclosure further relates to the use of compounds of formula (I), formula (II), formula (III) and Table A or their pharmaceutically acceptable salts, or pharmaceutical compositions comprising the same, in the preparation of drugs for treating and / or preventing diseases or conditions mediated by MK2.
[0133] The present disclosure further relates to the use of the compounds of formula (I), formula (II), formula (III) and Table A or their pharmaceutically acceptable salts or pharmaceutical compositions comprising the same in the preparation of a medicament for treating and / or preventing autoimmune disorders, chronic or acute inflammatory disorders, autoinflammatory disorders, fibrotic disorders, metabolic disorders, neoplasia and cardiovascular or cerebrovascular disorders; the autoimmune disorders, chronic or acute inflammatory disorders and autoinflammatory disorders are preferably selected from inflammatory bowel disease, ulcerative colitis, psoriasis, Crohn's disease (CD), multiple sclerosis, psoriasis, arthritis, ankylosing spondylitis, asthma, chronic obstructive pulmonary disease (COPD), cryopyrogenic periodic syndrome, Muckle-Wells syndrome (Muckle-Wells syndrome), and the like. syndrome), familial cold autoinflammatory syndrome, neonatal onset multisystem inflammatory disease, TNF receptor-associated periodic syndrome, acute and chronic pancreatitis, atherosclerosis, gout, acute respiratory distress syndrome, autoimmune hemolytic syndrome, autoimmune and inflammatory hepatitis, autoimmune neuropathy, autoimmune ovarian failure, autoimmune orchitis, autoimmune thrombocytopenia, systemic lupus erythematosus, vasculitis syndrome, hypophysitis, idiopathic platelet Purpura, pemphigus, autoimmune deafness, meningitis, myocarditis, gingivitis, enterocolitis, sinusitis, uveitis, ophthalmitis, optic neuritis, gastric ulcer, esophagitis, peritonitis, root periostitis, dermatomyositis, gastritis, myositis, bronchitis, novel coronavirus infection (COVID-19) and suppurative hidradenitis; the arthritis is preferably selected from rheumatoid arthritis (RA), psoriatic arthritis, osteoarthritis, juvenile arthritis, psoriatic arthritis, reactive arthritis and spondyloarthritis.
[0134] Preferably, the MK2-mediated disease or disorder of the present disclosure is selected from the group consisting of an autoimmune disorder, a chronic or acute inflammatory disorder, an autoinflammatory disorder, a fibrotic disorder, a metabolic disorder, neoplasia, and a cardiovascular or cerebrovascular disorder.
[0135] Preferably, the MK2-mediated disease or disorder of the present disclosure is selected from the group consisting of an autoimmune disorder, a chronic or acute inflammatory disorder, and an autoinflammatory disorder.
[0136] Preferably, the disease or disorder mediated by MK2 according to the present disclosure is a fibrotic disorder.
[0137] Preferably, the disease or disorder mediated by MK2 described in the present disclosure is a metabolic disorder.
[0138] Preferably, the disease or disorder mediated by MK2 according to the present disclosure is neoplasia.
[0139] Preferably, the disease or disorder mediated by MK2 described in the present disclosure is a cardiovascular or cerebrovascular disorder.
[0140] The autoimmune disorders, chronic or acute inflammatory disorders and autoinflammatory disorders of the present disclosure are preferably selected from inflammatory bowel disease, ulcerative colitis, psoriasis, Crohn's disease (CD), multiple sclerosis, psoriasis, arthritis, ankylosing spondylitis (also known as ankylosing spondylitis), asthma, chronic obstructive pulmonary disease (COPD), cryopyr protein-associated periodic syndrome, Muckle-Wells syndrome (Muckle-Wells syndrome), and the like. syndrome), familial cold autoinflammatory syndrome, neonatal onset multisystem inflammatory disease, TNF receptor-associated periodic syndrome, acute and chronic pancreatitis, atherosclerosis, gout, fibrotic disorders, liver fibrosis, idiopathic pulmonary fibrosis, kidney disease, sarcoidosis, scleroderma, anaphylaxis, diabetes (type 1 diabetes, type 2 diabetes), diabetic retinopathy, Still's disease, sarcoidosis, lung inflammation, acute respiratory distress syndrome, wet and dry age-related macular degeneration, autoimmune hemolytic syndrome, autoimmune and inflammatory hepatitis, autoimmune neuropathy, autoimmune ovarian failure, autoimmune orchitis, autoimmune thrombocytopenia, silicone implant-related autoimmune diseases, Sjogren's syndrome syndrome), familial Mediterranean fever, systemic lupus erythematosus, temporal arteritis, Takayasu's arteritis and giant cell arteritis, Behcet's disease, Wegener's granulomatosis, vitiligo, secondary blood expression of autoimmune diseases, anemia, drug-induced autoimmunity, Hashimoto's thyroiditis, vasculitis syndrome, hypophysitis, idiopathic thrombocytic purpura, metal-induced autoimmunity, myasthenia gravis, pemphigus, autoimmune deafness, Meniere's disease, Goodpasture's syndrome, Graves' disease, HW-related autoimmune syndrome, Gullain-Barre disease disease, Addison's disease, antiphospholipid syndrome, atopic dermatitis, celiac disease, Cushing's syndrome, dermatomyositis, idiopathic adrenal atrophy, idiopathic thrombocytopenia, Kawasaki syndrome, Lambert-Eaton syndromeSyndrome, pernicious anemia, hay fever, polyarteritis nodosa, primary biliary cirrhosis, primary sclerosing cholangitis, Raynaud's, Reiter's Syndrome, relapsing polychondritis, Schmidt's syndrome, thyrotoxicosis, sepsis, septic shock, endotoxin shock, exotoxin-induced toxic shock, gram negative sepsis sepsis), toxic shock syndrome, glomerulonephritis, peritonitis, interstitial cystitis, hyperoxia-induced inflammation, graft-versus-host reaction, graft-versus-host disease, allograft rejection, acute allograft rejection, chronic allograft rejection, early transplant rejection, acute allograft rejection, reperfusion injury, pain (preferably acute pain, chronic pain, neuralgia, muscular pain), chronic infection, meningitis, encephalitis, myocarditis, gingivitis, postoperative trauma, tissue damage, traumatic brain injury, enterocolitis, sinusitis Inflammation, uveitis, ophthalmitis, optic neuritis, gastric ulcer, esophagitis, peritonitis, gingival periostitis, dermatomyositis, gastritis, myositis, polymyalgia, pneumonia, bronchitis, novel coronavirus infection (COVID-19) and suppurative hidradenitis; more preferably selected from inflammatory bowel disease, ulcerative colitis, psoriasis, Crohn's disease (CD), multiple sclerosis, psoriasis, arthritis, ankylosing spondylitis (also called ankylosing spondylitis), asthma, chronic obstructive pulmonary disease (COPD), cryptopyrin-associated periodic syndrome, Muckle-Wells syndrome (Muckle-Wells syndrome), familial cold autoinflammatory syndrome, neonatal onset multisystem inflammatory disease, TNF receptor-associated periodic syndrome, acute and chronic pancreatitis, atherosclerosis, gout, acute respiratory distress syndrome, autoimmune hemolytic syndrome, autoimmune and inflammatory hepatitis, autoimmune neuropathy, autoimmune ovarian failure, autoimmune orchitis, autoimmune thrombocytopenia, systemic lupus erythematosus, vasculitis syndrome, hypophysitis, idiopathic thrombocytic purpura, pemphigus, autoimmune deafness, meningitis, myocarditis, gingivitis, enterocolitis, sinusitis, uveitis, ophthalmitis, optic neuritis, gastric ulcer, esophagitis, peritonitis, periostitis, dermatomyositis, gastritis, myositis, bronchitis, novel coronavirus infection (COVID-19), and hidradenitis suppurativa.
[0141] The above-mentioned arthritis is preferably selected from rheumatoid arthritis (RA), psoriatic arthritis, osteoarthritis, juvenile arthritis, psoriatic arthritis, reactive arthritis and spondyloarthritis.
[0142] The fibrotic disorder of the present disclosure is preferably selected from systemic sclerosis / scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scars, spinal cord injury, CNS scars, acute lung injury, pulmonary fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, chronic kidney disease, diabetic nephropathy, hypertension-induced nephropathy, digestive or gastrointestinal tract fibrosis, renal fibrosis, liver or gallbladder fibrosis, liver fibrosis, nonalcoholic steatohepatitis, hepatitis C, hepatocellular carcinoma, cirrhosis, primary biliary tract, Cirrhosis, cirrhosis due to fatty liver disease, cirrhosis due to alcoholic fatty liver disease, cirrhosis due to nonalcoholic steatosis / nonalcoholic fatty liver disease, radiation-induced fibrosis, fibrosis of the head and neck, gastrointestinal fibrosis, pulmonary fibrosis, primary sclerosing cholangitis, restenosis, cardiac fibrosis, endomyocardial fibrosis, atrial fibrosis, ophthalmic scarring, fibrosclerosis, fibrotic cancer, fibroids, fibromas, fibroadenomas, fibrosarcomas, transplant arteriopathy, keloids, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, and nephrogenic systemic fibrosis.
[0143] The metabolic disorder of the present disclosure is preferably selected from obesity, steroid resistance, glucose intolerance and metabolic syndrome.
[0144] The neoplasia of the present disclosure is preferably selected from the group consisting of angiogenic disorders, multiple myeloma, leukemia, acute lymphocytic leukemia, acute and chronic myeloid leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, promyelocytic leukemia, lymphoma, B-cell lymphoma, T-cell lymphoma, mantle cell lymphoma, hairy cell lymphoma, Burkitt's lymphoma, mast cell tumors, Hodgkin's disease, non-Hodgkin's disease, myelodysplastic syndrome, fibrosarcoma, rhabdomyosarcoma, astrocytoma, neuroblastoma, glioma, schwannoma, melanoma, seminoma, teratoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer, Kaposi's sarcoma, sarcoma), melanoma, teratoma, rhabdomyosarcoma, metastatic and skeletal disorders, cancers of the bone, mouth / throat, esophagus, larynx, stomach, intestine, colon, rectum, lung, liver, pancreas, nerves, brain, head and neck, throat, ovary, uterus, prostate, testicles, bladder, kidney, breast, gallbladder, cervix, thyroid, prostate and skin, non-small cell lung cancer, small cell lung cancer, glioma, glioblastoma multiforme, breast cancer (HR positive / HER2 negative metastatic breast cancer) and bone metastases.
[0145] The present disclosure relates to cardiovascular or cerebrovascular disorders preferably selected from atherosclerosis, restenosis of atherosclerotic coronary arteries, acute coronary syndrome, myocardial infarction, myocardial allograft vasculopathy, stroke, central nervous system disorders with inflammatory or apoptotic components, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, neuronal ischemia and peripheral neuropathy.
[0146] The active compound can be prepared into a form suitable for administration by any appropriate route, and the composition of the present disclosure can be prepared by conventional methods using one or more pharmaceutically acceptable carriers. Therefore, the active compound of the present disclosure can be formulated into various dosage forms for oral administration, injection (e.g., intravenous, intramuscular or subcutaneous) administration, inhalation or insufflation administration. The compounds of the present disclosure can also be formulated into dosage forms such as tablets, hard or soft capsules, aqueous or oily suspensions, emulsions, injections, dispersible powders or granules, suppositories, lozenges or syrups.
[0147] As a general guide, the active compound is preferably in a unit dose form, or in a form that a patient can self-administer in a single dose. The unit dose of the disclosed compound or composition can be expressed in tablets, capsules, cachets, bottled liquids, powders, granules, lozenges, suppositories, reconstituted powders or liquid preparations. Suitable unit doses can be 0.1 to 1000 mg.
[0148] The pharmaceutical composition of the present disclosure may contain one or more excipients in addition to the active compound, and the excipients are selected from the following ingredients: fillers (diluents), binders, wetting agents, disintegrants or excipients, etc. Depending on the administration method, the composition may contain 0.1 to 99% by weight of the active compound.
[0149] In some embodiments, the unit dose of the pharmaceutical composition is 0.001 mg-1000 mg.
[0150] In certain embodiments, the pharmaceutical composition contains 0.01-99.99% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution, based on the total weight of the composition. In certain embodiments, the pharmaceutical composition contains 0.1-99.9% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution. In certain embodiments, the pharmaceutical composition contains 0.5%-99.5% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution. In certain embodiments, the pharmaceutical composition contains 1%-99% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution. In certain embodiments, the pharmaceutical composition contains 2%-98% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution.
[0151] In certain embodiments, the pharmaceutical composition contains 0.01%-99.99% of a pharmaceutically acceptable excipient based on the total weight of the composition. In certain embodiments, the pharmaceutical composition contains 0.1%-99.9% of a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition contains 0.5%-99.5% of a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition contains 1%-99% of a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition contains 2%-98% of a pharmaceutically acceptable excipient.
[0152] Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients suitable for preparing tablets. These excipients may be inert excipients, granulating agents, disintegrants, binders and lubricants. These tablets may be uncoated or may be coated by known techniques that mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained release effect over a longer period of time.
[0153] Oral preparations may also be provided in soft gelatin capsules wherein the active ingredient is mixed with an inert solid diluent or wherein the active ingredient is mixed with a water-soluble carrier or an oily vehicle.
[0154] Aqueous suspensions contain the active substance and excipients suitable for preparing aqueous suspensions for mixing. Such excipients are suspending agents, dispersants or wetting agents. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents.
[0155] Oil suspensions can be prepared by suspending the active ingredient in a vegetable oil, or a mineral oil. The oil suspension may contain a thickener. The above-mentioned sweeteners and flavoring agents may be added to provide a palatable preparation. These compositions may be preserved by adding an antioxidant.
[0156] Pharmaceutical compositions of the present disclosure may also be in the form of oil-in-water emulsions. The oil phase may be a vegetable oil, or a mineral oil or a mixture thereof. Suitable emulsifiers may be naturally occurring phospholipids, and the emulsions may also contain sweeteners, flavoring agents, preservatives, and antioxidants. Such preparations may also contain a demulcent, a preservative, a coloring agent, and an antioxidant.
[0157] The pharmaceutical compositions of the present disclosure may be in the form of sterile injectable aqueous solutions. Acceptable vehicles or solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution. The sterile injectable formulation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in the oil phase. The injection or microemulsion may be injected into the patient's bloodstream by local mass injection. Alternatively, it is preferred that the solution and microemulsion be administered in a manner that maintains a constant circulating concentration of the disclosed compound. To maintain such a constant concentration, a continuous intravenous drug delivery device may be used. An example of such a device is the Deltec CADD-PLUS.TM.5400 intravenous injection pump.
[0158] Pharmaceutical compositions of the present disclosure can be in the form of sterile injection water or oil suspension for intramuscular and subcutaneous administration. The suspension can be prepared by known techniques with the above-mentioned suitable dispersants or wetting agents and suspending agents. Sterile injection preparations can also be sterile injection solutions or suspensions prepared in parenteral acceptable non-toxic diluents or solvents. In addition, sterile fixed oils can be conveniently used as solvents or suspension media. For this purpose, any blended fixed oils can be used. In addition, fatty acids can also be used to prepare injections.
[0159] The disclosed compounds may be administered in the form of suppositories for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid in the rectum and will therefore melt in the rectum to release the drug.
[0160] The compounds of the present disclosure can be administered by preparing water-suspended dispersible powders and granules by the addition of water. These pharmaceutical compositions can be prepared by mixing the active ingredient with a dispersing or wetting agent, a suspending agent, or one or more preservatives.
[0161] As is well known to those skilled in the art, the dosage of a drug depends on a variety of factors, including but not limited to the following factors: the activity of the specific compound used, the age of the patient, the weight of the patient, the health status of the patient, the behavior of the patient, the diet of the patient, the time of administration, the mode of administration, the rate of excretion, the combination of drugs, the severity of the disease, etc.; in addition, the best treatment method such as the mode of treatment, the daily dosage of the compound or the type of pharmaceutically acceptable salt can be verified according to traditional treatment regimens.
[0162] Terminology
[0163] Unless stated otherwise, the terms used in the specification and claims have the following meanings.
[0164] The term "alkyl" refers to a saturated straight-chain or branched aliphatic hydrocarbon group having 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (i.e., C 1-20 The alkyl group is preferably an alkyl group having 1 to 12 carbon atoms (i.e., C 1-12 alkyl), more preferably an alkyl group having 1 to 6 carbon atoms (i.e., C 1-6 Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2 ,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof. The alkyl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituent is preferably selected from one or more of a D atom, a halogen, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.
[0165] The term "alkylene" refers to a divalent alkyl group, wherein alkyl is as defined above, having from 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms (i.e., C 1-20 The alkylene group is preferably an alkylene group having 1 to 12 carbon atoms (i.e., C 1-12Alkylene), more preferably an alkylene group having 1 to 6 carbon atoms (i.e., C 1-6 Alkylene). Non-limiting examples include: -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH(CH2CH3)-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, etc. Alkylene can be substituted or unsubstituted, and when substituted, it can be substituted at any available point of attachment, and the substituent is preferably selected from one or more of D atoms, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0166] The term "alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond in the molecule, wherein the alkyl group is as defined above and has 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (i.e., C 2-12 The alkenyl group is preferably an alkenyl group having 2 to 6 carbon atoms (i.e., C 2-6 Alkenyl). Non-limiting examples include: vinyl, propenyl, isopropenyl, butenyl, etc. Alkenyl can be substituted or unsubstituted, and when substituted, it can be substituted at any available point of attachment, and the substituent is preferably selected from one or more of D atoms, alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0167] The term "alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond in the molecule, wherein alkyl is as defined above and has 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (i.e., C 2-12 The alkynyl group is preferably an alkynyl group having 2 to 6 carbon atoms (i.e., C 2-6 Alkynyl). Non-limiting examples include: ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc. Alkynyl can be substituted or unsubstituted, and when substituted, it can be substituted at any available point of attachment, and the substituent is preferably selected from one or more of D atoms, alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0168] The term "alkoxy" refers to -O-(alkyl), wherein alkyl is as defined above. Non-limiting examples include: methoxy, ethoxy, propoxy and butoxy, etc. Alkoxy can be substituted or unsubstituted, and when substituted, it can be substituted at any usable point of attachment, and the substituent is preferably selected from one or more of D atoms, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0169] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic all-carbon ring (i.e., monocyclic cycloalkyl) or polycyclic ring system (i.e., polycyclic cycloalkyl) having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., 3 to 20-membered cycloalkyl). The cycloalkyl is preferably a cycloalkyl having 3 to 12 ring atoms (i.e., 3 to 12-membered cycloalkyl), more preferably a cycloalkyl having 3 to 8 ring atoms (i.e., 3 to 8-membered cycloalkyl), and most preferably a cycloalkyl having 3 to 6 ring atoms (i.e., 3 to 6-membered cycloalkyl) or a cycloalkyl having 4 to 7 ring atoms (i.e., 4 to 7-membered cycloalkyl).
[0170] Non-limiting examples of the monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl and cyclooctyl.
[0171] The polycyclic cycloalkyl group includes: spirocycloalkyl group, fused cycloalkyl group and bridged cycloalkyl group.
[0172] The term "spirocycloalkyl" refers to a polycyclic system in which one carbon atom (called spiro atom) is shared between the rings, and the rings may contain one or more double bonds, or the rings may contain one or more heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxidized, i.e., to form sulfoxides or sulfones, but not including -OO-, -OS- or -SS-), provided that at least one all-carbon ring is contained and the connection point is on the all-carbon ring, and it has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., 5 to 20-membered spirocycloalkyl). The spirocycloalkyl preferably has 6 to 14 ring atoms (i.e., 6 to 14-membered spirocycloalkyl), and more preferably has 7 to 10 ring atoms (i.e., 7 to 10-membered spirocycloalkyl). The spirocycloalkyl includes monospirocycloalkyl and polyspirocycloalkyl (such as bispirocycloalkyl, etc.), preferably monospirocycloalkyl or bispirocycloalkyl, more preferably 3-yuan / 4-yuan, 3-yuan / 5-yuan, 3-yuan / 6-yuan, 4-yuan / 4-yuan, 4-yuan / 5-yuan, 4-yuan / 6-yuan, 5-yuan / 3-yuan, 5-yuan / 4-yuan, 5-yuan / 5-yuan, 5-yuan / 6-yuan, 5-yuan / 7-yuan, 6-yuan / 3-yuan, 6-yuan / 4-yuan, 6-yuan / 5-yuan, 6-yuan / 6-yuan, 6-yuan / 7-yuan, 7-yuan / 5-yuan or 7-yuan / 6-yuan monospirocycloalkyl. Non-limiting examples include:
[0173] Its connection point can be at any position;
[0174] wait.
[0175] The term "fused cycloalkyl" refers to a polycyclic system in which two adjacent carbon atoms are shared between the rings, which is a monocyclic cycloalkyl fused to one or more monocyclic cycloalkyls, or a monocyclic cycloalkyl fused to one or more heterocyclyls, aryls or heteroaryls, wherein the point of attachment is on the monocyclic cycloalkyl, which may contain one or more double bonds within the ring, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., 5 to 20-membered fused cycloalkyl). The fused cycloalkyl preferably has 6 to 14 ring atoms (i.e., 6 to 14-membered fused cycloalkyl), and more preferably has 7 to 10 ring atoms (i.e., 7 to 10-membered fused cycloalkyl). The fused cycloalkyl includes bicyclic fused cycloalkyl and polycyclic fused cycloalkyl (such as tricyclic fused cycloalkyl, tetracyclic fused cycloalkyl, etc.), preferably bicyclic fused cycloalkyl or tricyclic fused cycloalkyl, more preferably 3 yuan / 4 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 3 yuan, 5 yuan / 4 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan, 5 yuan / 7 yuan, 6 yuan / 3 yuan, 6 yuan / 4 yuan, 6 yuan / 5 yuan, 6 yuan / 6 yuan, 6 yuan / 7 yuan, 7 yuan / 5 yuan or 7 yuan / 6 yuan bicyclic fused cycloalkyl. Non-limiting examples include:
[0176] , whose connection points can be at any position;
[0177]
[0178] wait.
[0179] The term "bridged cycloalkyl" refers to a full carbon polycyclic system that shares two carbon atoms that are not directly connected between the rings, which may contain one or more double bonds in the ring and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (i.e., 5 to 20-membered bridged cycloalkyl). The bridged cycloalkyl preferably has a bridged cycloalkyl of 6 to 14 carbon atoms (i.e., 6 to 14-membered bridged cycloalkyl), and more preferably has a bridged cycloalkyl of 7 to 10 carbon atoms (i.e., 7 to 10-membered bridged cycloalkyl). The bridged cycloalkyl includes bicyclic bridged cycloalkyl and polycyclic bridged cycloalkyl (e.g., tricyclic bridged cycloalkyl, tetracyclic bridged cycloalkyl, etc.), preferably bicyclic bridged cycloalkyl or tricyclic bridged cycloalkyl. Non-limiting examples include:
[0180] Its connection point can be at any position.
[0181] The cycloalkyl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, oxo, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0182] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic heterocycle (i.e., a monocyclic heterocyclyl) or a polycyclic heterocyclic ring system (i.e., a polycyclic heterocyclyl), which contains at least one (e.g., 1, 2, 3 or 4) heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxoed, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS- or -SS-) in the ring, and has 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., a 3- to 20-membered heterocyclyl). The heterocyclic group is preferably a heterocyclic group having 3 to 12 ring atoms (i.e., a 3- to 12-membered heterocyclic group); further preferably a heterocyclic group having 3 to 8 ring atoms (i.e., a 3- to 8-membered heterocyclic group); more preferably a heterocyclic group having 3 to 6 ring atoms (i.e., a 3- to 6-membered heterocyclic group) or a heterocyclic group having 4 to 7 ring atoms (i.e., a 4- to 7-membered heterocyclic group) or a heterocyclic group having 5 to 8 ring atoms (i.e., a 5- to 8-membered heterocyclic group) or a heterocyclic group having 4 to 8 ring atoms (i.e., a 4- to 8-membered heterocyclic group); most preferably a heterocyclic group having 5 or 6 ring atoms (i.e., a 5- or 6-membered heterocyclic group).
[0183] Non-limiting examples of the monocyclic heterocyclic group include pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and homopiperazinyl.
[0184] The polycyclic heterocyclic group includes a spiro heterocyclic group, a fused heterocyclic group and a bridged heterocyclic group.
[0185] The term "spiroheterocyclyl" refers to a polycyclic heterocyclic ring system in which the rings share one atom (called a spiro atom), which may contain one or more double bonds in the ring and at least one (e.g., 1, 2, 3 or 4) heteroatom selected from nitrogen, oxygen and sulfur in the ring (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxidized, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS- or -SS-), provided that it contains at least one monocyclic heterocyclic group and the point of attachment is on the monocyclic heterocyclic group, which has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., a 5- to 20-membered spiroheterocyclyl). The spiro heterocyclic radical preferably has a spiro heterocyclic radical of 6 to 14 ring atoms (i.e., a 6 to 14-membered spiro heterocyclic radical), more preferably a spiro heterocyclic radical of 7 to 10 ring atoms (i.e., a 7 to 10-membered spiro heterocyclic radical). The spiro heterocyclic radical includes a monospiro heterocyclic radical and a polyspiro heterocyclic radical (such as a bispiro heterocyclic radical, etc.), preferably a monospiro heterocyclic radical or a bispiro heterocyclic radical, more preferably a 3-yuan / 4-yuan, 3-yuan / 5-yuan, 3-yuan / 6-yuan, 4-yuan / 4-yuan, 4-yuan / 5-yuan, 4-yuan / 6-yuan, 5-yuan / 3-yuan, 5-yuan / 4-yuan, 5-yuan / 5-yuan, 5-yuan / 6-yuan, 5-yuan / 7-yuan, 6-yuan / 3-yuan, 6-yuan / 4-yuan, 6-yuan / 5-yuan, 6-yuan / 6-yuan, 6-yuan / 7-yuan, 7-yuan / 5-yuan or 7-yuan / 6-yuan monospiro heterocyclic radical. Non-limiting examples include:
[0186] wait.
[0187] The term "fused heterocyclyl" refers to a polycyclic heterocyclic ring system which shares two adjacent atoms between the rings, which may contain one or more double bonds within the ring, and which contains at least one (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur within the ring (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxidized, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS-, or -SS-), which is a monocyclic heterocyclyl fused to one or more monocyclic heterocyclyls, or a monocyclic heterocyclyl fused to one or more of cycloalkyl, aryl, or heteroaryl, wherein the point of attachment is on the monocyclic heterocyclyl, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered fused heterocyclyl). The fused heterocyclic group preferably has a fused heterocyclic group of 6 to 14 ring atoms (i.e., a 6 to 14-membered fused heterocyclic group), and more preferably has a fused heterocyclic group of 7 to 10 ring atoms (i.e., a 7 to 10-membered fused heterocyclic group). The fused heterocyclic group includes bicyclic and polycyclic fused heterocyclic groups (such as tricyclic fused heterocyclic groups, tetracyclic fused heterocyclic groups, etc.), preferably a bicyclic fused heterocyclic group or a tricyclic fused heterocyclic group, more preferably a 3-yuan / 4-yuan, 3-yuan / 5-yuan, 3-yuan / 6-yuan, 4-yuan / 4-yuan, 4-yuan / 5-yuan, 4-yuan / 6-yuan, 5-yuan / 3-yuan, 5-yuan / 4-yuan, 5-yuan / 5-yuan, 5-yuan / 6-yuan, 5-yuan / 7-yuan, 6-yuan / 3-yuan, 6-yuan / 4-yuan, 6-yuan / 5-yuan, 6-yuan / 6-yuan, 6-yuan / 7-yuan, 7-yuan / 5-yuan or 7-yuan / 6-yuan bicyclic fused heterocyclic group. Non-limiting examples include:
[0188]
[0189] wait.
[0190] The term "bridged heterocyclic group" refers to a polycyclic heterocyclic ring system that shares two atoms that are not directly connected between the rings, which may contain one or more double bonds in the ring, and which contains at least one (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur in the ring (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxidized, i.e., to form sulfoxides or sulfones, but does not include -OO-, -OS-, or -SS-), and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., 5 to 20-membered bridged heterocyclic groups). The bridged heterocyclic group is preferably a bridged heterocyclic group having 6 to 14 ring atoms (i.e., 6 to 14-membered bridged heterocyclic groups), and more preferably a bridged heterocyclic group having 7 to 10 ring atoms (i.e., 7 to 10-membered bridged heterocyclic groups). According to the number of constituent rings, it can be divided into bicyclic bridged heterocyclic groups and polycyclic bridged heterocyclic groups (such as tricyclic bridged heterocyclic groups, tetracyclic bridged heterocyclic groups, etc.), preferably bicyclic bridged heterocyclic groups or tricyclic bridged heterocyclic groups. Non-limiting examples include:
[0191] wait.
[0192] The heterocyclic group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic groupoxy, hydroxyl, hydroxyalkyl, oxo, cyano, amino, nitro, cycloalkyl, heterocyclic group, aryl and heteroaryl.
[0193] The term "aryl" refers to a monocyclic all-carbon aromatic ring (i.e., a monocyclic aromatic group) or a polycyclic aromatic ring system (i.e., a polycyclic aromatic group) having a conjugated π electron system, which has 6 to 14 (e.g., 6, 7, 8, 9, 10, 11, 12, 13 or 14) ring atoms (i.e., a 6- to 14-membered aromatic group). The aryl group is preferably an aromatic group having 6 to 10 ring atoms (i.e., a 6- to 10-membered aromatic group). The monocyclic aromatic group is, for example, phenyl. Non-limiting examples of the polycyclic aromatic group include: naphthyl, anthracenyl, phenanthryl, etc. The polycyclic aromatic group also includes a phenyl group fused with one or more heterocyclic groups or cycloalkyl groups, or a naphthyl group fused with one or more heterocyclic groups or cycloalkyl groups, wherein the connection point is on the phenyl group or the naphthyl group, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic aromatic ring system, and non-limiting examples include:
[0194] wait.
[0195] The aryl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, oxo, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0196] The term "heteroaryl" refers to a monocyclic heteroaromatic ring (i.e., a monocyclic heteroaryl) or a polycyclic heteroaromatic ring system (i.e., a polycyclic heteroaryl) having a conjugated π electron system, which contains at least one (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur in the ring (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxidized, i.e., to form sulfoxides or sulfones, but does not include -OO-, -OS-, or -SS-), and has 5 to 14 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms (i.e., a 5- to 14-membered heteroaryl). The heteroaryl is preferably a heteroaryl having 5 to 10 ring atoms (i.e., a 5- to 10-membered heteroaryl), and more preferably a heteroaryl having 5 or 6 ring atoms (i.e., a 5- or 6-membered heteroaryl).
[0197] The monocyclic heteroaryl group includes, but is not limited to, furanyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furazanyl, pyrrolyl, N-alkylpyrrolyl, pyridinyl, pyrimidinyl, pyridonyl (e.g. ), N-alkyl pyridone (such as etc.), pyrazinone, pyrazinyl, pyridazinyl, wait.
[0198] The polycyclic heteroaryl, non-limiting examples include: indolyl, indazolyl, quinolyl, isoquinolyl, quinoxalinyl, phthalazinyl, benzimidazolyl, benzothiophenyl, quinazolinyl, benzothiazolyl, carbazolyl, etc. The polycyclic heteroaryl also includes a monocyclic heteroaryl fused with one or more aromatic groups, wherein the connection point is on the aromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system. The polycyclic heteroaryl also includes a monocyclic heteroaryl fused with one or more cycloalkyl or heterocyclic groups, wherein the connection point is on the monocyclic heteroaromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system. Non-limiting examples include:
[0199]
[0200] wait.
[0201] The heteroaryl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0202] The term "amino protecting group" refers to a group that is easily removed and introduced on the amino group in order to keep the amino group unchanged when other parts of the molecule are reacted. Non-limiting examples include: (trimethylsilyl)ethoxymethyl (SEM), tetrahydropyranyl, tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), methyloxycarbonyl (Fmoc), allyloxycarbonyl (Alloc), trimethylsilylethoxycarbonyl (Teoc), methoxycarbonyl, ethoxycarbonyl, phthaloyl (Pht), p-toluenesulfonyl (Tos), trifluoroacetyl (Tfa), trityl (Trt), 2,4-dimethoxybenzyl (DMB), 2-tetrahydropyranyl (THP), acetyl, benzyl, allyl, p-methoxybenzyl, etc.; preferably (trimethylsilyl)ethoxymethyl (SEM) or 2-tetrahydropyranyl (THP).
[0203] The term "alkoxyalkyl" refers to an alkyl group substituted with one or more alkoxy groups, wherein alkyl and alkoxy are as defined above. Non-limiting examples include: -CH2OCH3, -CH2OCH2CH3, and -CH2OtBu.
[0204] The term "aminoalkyl" refers to an alkyl group substituted with one or more amino groups, wherein alkyl is as defined above. Non-limiting examples include: -CH2NH2.
[0205] The term "cycloalkylalkyl" refers to an alkyl group substituted with one or more cycloalkyl groups, wherein alkyl and cycloalkyl are as defined above.
[0206] The term "heterocyclylalkyl" refers to an alkyl group substituted with one or more heterocyclyl groups, wherein alkyl and heterocyclyl are as defined above.
[0207] The term "arylalkyl" refers to an alkyl group substituted with one or more aryl groups, wherein alkyl and aryl are as defined above.
[0208] The term "heteroarylalkyl" refers to an alkyl group substituted with one or more heteroaryl groups, wherein alkyl and heteroaryl are as defined above.
[0209] The term "heterocyclyloxy" refers to heterocyclyl-O-, wherein heterocyclyl is as defined above.
[0210] The term "cycloalkyloxy" refers to a cycloalkyl-O- group in which cycloalkyl is as defined above.
[0211] The term "aryloxy" refers to an aryl-O- group in which aryl is as defined above.
[0212] The term "heteroaryloxy" refers to heteroaryl-O-, wherein heteroaryl is as defined above.
[0213] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
[0214] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.
[0215] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.
[0216] The term "deuterated alkoxy" refers to an alkoxy group substituted with one or more deuterium atoms, wherein alkoxy is as defined above.
[0217] The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above; non-limiting examples include:
[0218] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0219] The term "hydroxy" refers to -OH.
[0220] The term "amino" refers to -NH2.
[0221] The term "cyano" refers to -CN.
[0222] The term "nitro" refers to -NO2.
[0223] The term "oxo" or "oxo" refers to "=0".
[0224] The term "carbonyl" refers to C=O.
[0225] The term "carboxy" refers to -C(O)OH.
[0226] The term "carboxylate" refers to -C(O)O(alkyl), -C(O)O(cycloalkyl), (alkyl)C(O)O- or (cycloalkyl)C(O)O-, wherein alkyl and cycloalkyl are as defined above.
[0227] The disclosed compounds may exist in specific stereoisomeric forms. The term "stereoisomer" refers to isomers with identical structures but different arrangements of atoms in space. It includes cis and trans (or Z and E) isomers, (-)- and (+)-isomers, (R)- and (S)-enantiomers, diastereomers, (D)- and (L)-isomers, tautomers, atropisomers, conformers and mixtures thereof (such as racemates, mixtures of diastereomers). Substituents in the disclosed compounds may have additional asymmetric atoms. All of these stereoisomers and their mixtures are included within the scope of the present disclosure. Optically active (-)- and (+)-isomers, (R)- and (S)-enantiomers and (D)- and (L)-isomers may be prepared by chiral synthesis, chiral reagents or other conventional techniques. An isomer of a compound disclosed herein can be prepared by asymmetric synthesis or chiral auxiliary, or, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereoisomer salt is formed with an appropriate optically active acid or base, and then the diastereoisomers are separated by conventional methods known in the art to obtain pure isomers. In addition, the separation of enantiomers and diastereoisomers is usually completed by chromatography.
[0228] In the chemical structures of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if there are chiral isomers in the chemical structure, the bond Can be or include both and For all carbon-carbon double bonds, even if only one configuration is named, both the Z and E configurations are included.
[0229] The compounds of the present disclosure may exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to a structural isomer that exists in equilibrium and is easily converted from one isomeric form to another isomeric form. It includes all possible tautomers, i.e., in the form of a single isomer or in the form of a mixture of any proportions of the tautomers. Non-limiting examples include: keto-enol, imine-enamine, lactam-lactim, etc. An example of a lactam-lactim equilibrium is shown below:
[0230]
[0231] For example, when referring to pyrazolyl, it is understood to include either or a mixture of two tautomers of the following two structures:
[0232]
[0233] All tautomeric forms are within the scope of the present disclosure, and the naming of compounds does not exclude any tautomer.
[0234] The compounds of the present disclosure include all suitable isotopic derivatives of the compounds thereof. The term "isotopic derivative" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes that can be introduced into the compounds of the present disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, for example, respectively. 2 H (deuterium, D), 3 H (tritium, T), 11 C. 13 C. 14 C. 15 N. 17 O. 18 O. 32 p. 33 p. 33 S. 34 S. 35 S. 36 S. 18 F. 36 Cl, 82 Br, 123 I. 124 I. 125 I. 129 I and 131 I, etc., preferably deuterium.
[0235] Compared with non-deuterated drugs, deuterated drugs have the advantages of reducing toxic side effects, increasing drug stability, enhancing therapeutic effects, and extending drug biological half-life. All isotopic composition changes of the compounds disclosed herein, whether radioactive or not, are included in the scope of the present disclosure. Each available hydrogen atom connected to a carbon atom can be independently replaced by a deuterium atom, wherein the replacement of deuterium can be partial or complete, and partial deuterium replacement means that at least one hydrogen is replaced by at least one deuterium.
[0236] Compounds of the present disclosure, when a position is specifically designated as "deuterium" or "D", the position is understood to have an abundance of deuterium that is at least 1000 times greater than the natural abundance of deuterium (which is 0.015%) (i.e., at least 15% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 1000 times greater than the natural abundance of deuterium (i.e., at least 15% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 2000 times greater than the natural abundance of deuterium (i.e., at least 30% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 3000 times greater than the natural abundance of deuterium (i.e., at least 45% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 3340 times greater than the natural abundance of deuterium (i.e., at least 50.1% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 3500 times greater than the natural abundance of deuterium (i.e., at least 52.5% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 4000 times greater than the natural abundance of deuterium (i.e., at least 60% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 4500 times greater than the natural abundance of deuterium (i.e., at least 67.5% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 5000 times greater than the natural abundance of deuterium (i.e., at least 75% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 5500 times greater than the natural abundance of deuterium (i.e., at least 82.5% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6000 times greater than the natural abundance of deuterium (i.e., at least 90% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6333.3 times greater than the natural abundance of deuterium (i.e., at least 95% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6466.7 times greater than the natural abundance of deuterium (i.e., at least 97% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6600 times greater than the natural abundance of deuterium (i.e., at least 99% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6633.3 times greater than the natural abundance of deuterium (ie, at least 99.5% deuterium incorporation).
[0237] "Optionally" or "optionally" means that the event or environment described later can but does not necessarily occur, and includes two situations in which the event or environment occurs or does not occur. For example, "alkyl optionally (optionally) substituted with halogen or cyano" includes the situation in which alkyl is substituted with halogen or cyano and the situation in which alkyl is not substituted with halogen and cyano.
[0238] "Substitution" or "substituted" means that one or more hydrogen atoms, preferably 1 to 6, more preferably 1 to 3 hydrogen atoms in a group are replaced independently by a corresponding number of substituents. Those skilled in the art can determine possible or impossible substitutions (by experiment or theory) without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated bond (such as an alkene).
[0239] "Pharmaceutical composition" means a mixture containing one or more compounds described herein or their pharmaceutically acceptable salts and other chemical components, as well as other components such as pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredients, and thus exert biological activity.
[0240] "Pharmaceutically acceptable salts" refer to salts of the compounds of the present disclosure, which may be selected from inorganic or organic salts. Such salts are safe and effective when used in mammals and have the desired biological activity. They may be prepared separately during the final isolation and purification of the compound, or by reacting a suitable group with a suitable base or acid. Bases commonly used to form pharmaceutically acceptable salts include inorganic bases, such as sodium hydroxide and potassium hydroxide, and organic bases, such as ammonia. Acids commonly used to form pharmaceutically acceptable salts include inorganic acids and organic acids.
[0241] The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with patient tissues without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio, and effective for the intended use.
[0242] As used herein, the singular form of "a," "an," and "the" include plural references and vice versa unless the context clearly dictates otherwise.
[0243] When the term "about" is applied to a parameter such as pH, concentration, temperature, etc., it indicates that the parameter can vary by ±10%, and sometimes more preferably within ±5%. As will be understood by those skilled in the art, when a parameter is not critical, numbers are generally given only for illustrative purposes and not for limitation.
[0244] Synthesis method of the disclosed compound
[0245] In order to achieve the purpose of this disclosure, this disclosure adopts the following technical solutions:
[0246] Solution 1
[0247] The present invention discloses a method for preparing a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:
[0248]
[0249] The compound represented by the general formula (IA) or its salt is deprotected under acidic conditions to obtain the compound represented by the general formula (I) or its pharmaceutically acceptable salt;
[0250] in:
[0251] PG is an amino protecting group; preferably, PG is SEM or THP;
[0252] R 4 is a hydrogen atom;
[0253] Ring A, Ring B, Ring C, X, Y, Z, R 0 , R 1 , R 2 , R 3 , m, n and p are as defined in the general formula (I).
[0254] Solution 2
[0255] The present invention discloses a method for preparing a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:
[0256]
[0257] The compound represented by the general formula (IIA) or a salt thereof is subjected to acidic conditions to remove the protecting group to obtain the compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof;
[0258] in:
[0259] PG is an amino protecting group; preferably, PG is SEM or THP;
[0260] Ring A, Ring B, Ring C, Y, Z, R 1 , R 2 , R 3 , m, n and p are as defined in the general formula (II).
[0261] Option 3
[0262] The present invention discloses a method for preparing a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:
[0263]
[0264] The compound represented by the general formula (IIIA) or a salt thereof is subjected to acidic conditions to remove the protecting group to obtain the compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof;
[0265] in:
[0266] PG is an amino protecting group; preferably, PG is SEM or THP;
[0267] Y, Z, R 1a , R 1b , R 1c , R 1d , R 2a , R 2b , R 2c , R 3a , R 3b , R 3c , Q and E are as defined in the general formula (III).
[0268] The reagents providing acidic conditions in the above synthesis scheme include but are not limited to hydrogen chloride, a 1,4-dioxane solution of hydrogen chloride, trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, methanesulfonic acid, nitric acid, phosphoric acid, p-toluenesulfonic acid, Me3SiCl, TMSOTf and mixtures thereof; preferably, the reagent providing acidic conditions is a 1,4-dioxane solution of trifluoroacetic acid or hydrogen chloride.
[0269] The above reaction is preferably carried out in a solvent, and the solvent used includes but is not limited to: N-methylpyrrolidone, ethylene glycol dimethyl ether, acetic acid, methanol, ethanol, acetonitrile, n-butanol, toluene, tetrahydrofuran, dichloromethane, petroleum ether, ethyl acetate, n-hexane, dimethyl sulfoxide, 1,4-dioxane, water, N,N-dimethylformamide, N,N-dimethylacetamide, 1,2-dibromoethane and mixtures thereof. DETAILED DESCRIPTION
[0270] The following embodiments are used to further describe the present disclosure, but these embodiments are not intended to limit the scope of the present disclosure.
[0271] Example
[0272] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10 -6 The unit of (ppm) is given. NMR measurements were performed using a Bruker AVANCE-400 nuclear magnetic spectrometer or a Bruker AVANCE NEO 500M, with deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD) as the measurement solvent, and tetramethylsilane (TMS) as the internal standard.
[0273] MS was measured using Agilent 1200 / 1290 DAD-6110 / 6120 Quadrupole MS liquid spectrometer-mass spectrometer (manufacturer: Agilent, MS model: 6110 / 6120 Quadrupole MS).
[0274] waters ACQuity UPLC-QD / SQD (Manufacturer: waters, MS model: waters ACQuity QdaDetector / waters SQ Detector)
[0275] THERMO Ultimate 3000-Q Exactive (Manufacturer: THERMO, MS model: THERMOQExactive)
[0276] High performance liquid chromatography (HPLC) analysis was performed using Agilent HPLC 1200DAD, Agilent HPLC 1200VWD and Waters HPLC e2695-2489.
[0277] Chiral HPLC analysis was performed using an Agilent 1260DAD high performance liquid chromatograph.
[0278] High performance liquid chromatography was performed using Waters 2545-2767, Waters 2767-SQ Detecor2, Shimadzu LC-20AP and Gilson GX-281 preparative chromatographs.
[0279] Chiral preparations were performed using a Shimadzu LC-20AP preparative chromatograph.
[0280] The CombiFlash rapid preparation instrument used was Combiflash Rf200 (TELEDYNE ISCO).
[0281] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The silica gel plate used in thin layer chromatography (TLC) adopts a specification of 0.15mm-0.2mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm-0.5mm.
[0282] Silica gel column chromatography generally uses Yantai Huanghai Silica Gel 200-300 mesh silica gel as the carrier.
[0283] Average kinase inhibition rate and IC 50 The values were determined using NovoStar microplate reader (BMG, Germany).
[0284] The known starting materials of the present invention can be synthesized by methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, AccelaChemBio Inc, Bid Pharmaceuticals, Darui Chemicals and other companies.
[0285] Unless otherwise specified in the examples, all reactions can be carried out under an argon atmosphere or a nitrogen atmosphere.
[0286] Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a capacity of about 1L.
[0287] Hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.
[0288] The pressurized hydrogenation reaction uses a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or a HC2-SS hydrogenator.
[0289] The hydrogenation reaction is usually carried out by evacuating the vacuum, filling with hydrogen, and repeating the operation three times.
[0290] The microwave reaction was carried out using a CEM Discover-S 908860 microwave reactor.
[0291] Unless otherwise specified in the examples, the solution refers to an aqueous solution.
[0292] Unless otherwise specified in the examples, the reaction temperature is room temperature, 20°C to 30°C.
[0293] The reaction progress in the embodiment is monitored by thin layer chromatography (TLC), the developing solvent used in the reaction, the eluent system of column chromatography used for purifying the compound and the developing solvent system of thin layer chromatography include: A: dichloromethane / methanol system, B: n-hexane / ethyl acetate system, C: petroleum ether / ethyl acetate system, the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.
[0294] Example 1
[0295] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidine
[0296] -2-yl)propan-2-ol 1
[0297]
[0298] first step
[0299] 6-Chloro-3-iodo-1H-pyrazolo[3,4-d]pyrimidine 1b
[0300] 6-Chloro-1H-pyrazolo[3,4-d]pyrimidine 1a (3 g, 19.41 mmol, Bidex Pharmaceuticals) was dissolved in N,N-dimethylformamide (30 mL, Sinopharm), and N-iodosuccinimide (5.24 g, 23.29 mmol, Shaoyuan) was added under stirring at room temperature, and the oil bath was heated to 110°C and stirred for 2 hours. The mixture was cooled to room temperature, diluted with 50 mL of water, extracted with ethyl acetate (50 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the title compound 1b (5.44 g, yield: 99.93%).
[0301] MS m / z(ESI):281.0[M+1]
[0302] Step 2
[0303] 6-Chloro-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-d]pyrimidine 1c
[0304] Compound 1b (5.44 g, 19.39 mmol) was dissolved in N,N-dimethylformamide (50 mL, Adamas), cooled to 0°C, sodium hydride (1.17 g, purity 60%, 29.25 mmol, Chinese medicine) was added, reacted at 0°C for 0.5 hours, 2-(trimethylsilyl)ethoxymethyl chloride (3.9 g, 23.39 mmol) was added, reacted at room temperature for 2 hours, 50 mL of saturated ammonium chloride solution was added, extracted with ethyl acetate (50 mL×3), the organic phases were combined, washed with 30 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography with eluent system C to obtain the title compound 1c (5.31 g, yield: 66.65%).
[0305] MS m / z(ESI):411.0[M+1]
[0306] Step 3
[0307] N-(3,5-difluoropyridin-2-yl)-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine 1d
[0308] 3,5-Difluoropyridin-2-amine (304 mg, 2.34 mmol) was dissolved in N,N-dimethylformamide (50 mL, Adamas), cooled to 0°C under nitrogen protection, added with lithium bis(trimethylsilyl)amide (1 M, 2.94 mL, Adamas), reacted at 0°C for 0.5 hours, and added with compound 1c (800 mg, 1.95 mmol). The mixture was reacted at room temperature for 1 hour, and 50 mL of saturated ammonium chloride solution was added, extracted with ethyl acetate (50 mL×3), the organic phases were combined, washed with 30 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system C to obtain the title compound 1d (570 mg, yield: 58.02%).
[0309] MS m / z(ESI):504.8[M+1]
[0310] Step 4
[0311] (E)-1-(3-Bromo-4-methylphenyl)-3-(dimethylamino)prop-2-en-1-one 1f
[0312] 1-(3-bromo-4-methylphenyl)ethane-1-one 1e (3 g, 14.08 mmol) was dissolved in N,N-dimethylformamide (20 mL, Adamas), 1,1-dimethoxy-N,N-dimethyl-methylamine (13.5 g, 113.29 mmol Adamas) was added, and the mixture was heated to 70°C for 24 hours. 50 mL of water was added, and the mixture was extracted with dichloromethane (50 mL×3), the organic phases were combined, washed with 30 mL of water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the title compound 1f (3.7 g, yield: 98.00%).
[0313] MS m / z(ESI):270.0[M+1]
[0314] Step 5
[0315] 2-(4-(3-bromo-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 1g
[0316] Compound 1f (3.7 g, 13.80 mmol) was dissolved in N,N-dimethylformamide (50 mL, Adamas), potassium carbonate (5 g, 36.18 mmol, Sinopharm), 2-hydroxy-2-methylpropionamidine hydrochloride (5.7 g, 41.13 mmol, Aikon), and heated to 65°C for 24 hours. 50 mL of water was added, extracted with dichloromethane (50 mL × 3), the organic phases were combined, washed with 30 mL of water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system C to obtain the title compound 1g (3.4 g, yield: 80.21%). MS m / z (ESI): 309.0 [M+1]
[0317] Step 6
[0318] 2-(4-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-yl)propan-2-ol 1h
[0319] Compound 1g (2g, 6.51mmol) was dissolved in 1,4-dioxane (80mL, Adamas), and bis-pinacol diborane (4.2g, 16.54mmol, Shaoyuan), potassium acetate (2.6g, 26.49mmol, Sinopharm), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (472.5mg, 0.65mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 1.5 hours. Filter, concentrate the filtrate under reduced pressure, and purify the residue by column chromatography with eluent system C to obtain the title compound 1h (1.7g, yield: 73.71%).
[0320] MS m / z(ESI):355.3[M+1]
[0321] Step 7
[0322] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[2-(trimethylsilyl)ethoxy)methyl]
[0323] [3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 1i
[0324] Compound 1d (570 mg, 1.13 mmol) was dissolved in 1,4-dioxane (6 mL, Adamas) and water (0.6 mL), and compound 1h (480 mg, 1.35 mmol), cesium carbonate (1.1 g, 3.38 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (83 mg, 0.11 mmol Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filtered, the filtrate was concentrated under reduced pressure to obtain the title compound 1i (680 mg, yield: 99.50%).
[0325] MS m / z(ESI):605.0[M+1]
[0326] Step 8
[0327] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidine
[0328] -2-yl)propan-2-ol 1
[0329] Compound 1i (680 mg, 1.12 mmol) was dissolved in dichloromethane (6 mL, Chinese medicine), trifluoroacetic acid (4.62 g, 40.52 mmol Adamas) was added, and the mixture was reacted at room temperature for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography with eluent system A to obtain the title compound 1 (75 mg, yield: 14.06%).
[0330] MS m / z(ESI):474.9[M+1]
[0331] 1 H NMR (500MHz, DMSO-d6): δ13.58(s,1H),10.02(s,1H),9.01(s,1H),8.86-8.85(m,1H),8.49(s,1H),8.37(s,1H),8 .30-8.29(m,1H),8.06-8.02(m,1H),7.60-7.58(m,1H),5.34-5.32(m,1H),5.15(s,1H),2.51(s,3H),1.56(s,6H).
[0332] Example 2
[0333] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-b]pyrazin-3-yl)-4-methylphenyl)pyrimidine
[0334] -2-yl)propan-2-ol
[0335]
[0336]
[0337] first step
[0338] 6-Chloro-3-iodo-1H-pyrazolo[3,4-b]pyrazine 2b
[0339] 6-Chloro-1H-pyrazolo[3,4-b]pyrazine 2a (1 g, 6.47 mmol, Shao Yuan) was dissolved in N,N-dimethylformamide (10 mL), and N-iodosuccinimide (2.2 g, 9.77 mmol, Shao Yuan) was added, and the mixture was reacted at 110°C for 2 hours. The reaction solution was cooled to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by column chromatography with eluent system C to obtain the title compound 2b (1.5 g, yield: 82.66%).
[0340] MS m / z(ESI):280.9[M+1]
[0341] Step 2
[0342] 6-Chloro-3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyrazine 2c
[0343] Compound 2b (1.5 g, 5.34 mmol) was dissolved in tetrahydrofuran (20 mL), 3,4-dihydro-2H-pyran (675 mg, 8.02 mmol, Adamas) and p-toluenesulfonic acid (105 mg, 609.74 μmol, Chinese medicine) were added at room temperature, and stirred at 55°C for 3 hours. The reaction solution was diluted with water and extracted with ethyl acetate. The organic phase was concentrated and the residue was purified by column chromatography with eluent system C to obtain the title compound 2c (1.8 g, yield: 92.31%).
[0344] MS m / z(ESI):280.8[M-83]
[0345] Step 3
[0346] N-(3,5-difluoropyridin-2-yl)-3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyrazin-6-amine 2d
[0347] 2-Amino-3,5-difluoropyridine (129 mg, 991.58 μmol, Bid) was dissolved in tetrahydrofuran (2 mL), the reaction solution was cooled to 0°C, sodium hydride (48 mg, 1.25 mmol, purity 60%) was added, and stirring was continued for half an hour. A tetrahydrofuran solution of compound 2c (300 mg, 822.88 μmol) was added. After addition, the reaction was allowed to react at 75°C for 30 minutes, and the reaction was quenched with saturated ammonium chloride solution, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated. The residue was purified by column chromatography with eluent system C to obtain the title compound 2d (285 mg, yield: 75.58%).
[0348] MS m / z(ESI):459.0[M+1]
[0349] Step 4
[0350] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyrazine
[0351] -3-yl)-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 2e
[0352] Compound 2d (120 mg, 261.89 μmol), compound 1h (93 mg, 262.52 μmol), cesium carbonate (255 mg, 782.64 μmol, Shaoyuan) and [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (20 mg, 27.33 μmol, Shaoyuan) were placed in water (0.2 mL) and 1,4-dioxane (2 mL), and nitrogen was replaced 3 times. The reaction solution was reacted at 100 ° C for 3 hours. The reaction solution was diluted with water, extracted with ethyl acetate, the organic phase was dried, filtered, and the filtrate was concentrated to obtain the crude title compound 2e (145 mg), which was used directly in the next step without purification.
[0353] MS m / z(ESI):559.0[M+1]
[0354] Step 5
[0355] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-b]pyrazin-3-yl)-4-methylphenyl)pyrimidine
[0356] -2-yl)propan-2-ol
[0357] Compound 2e (145 mg, 259.58 μmol) was dissolved in ethyl acetate (2 mL), and a solution of hydrogen chloride in 1,4-dioxane (0.65 mL, 4 M, Adamas) was added. The reaction solution was reacted at room temperature for 1 hour. The reaction solution was concentrated, and the residue was purified by high performance liquid chromatography (chromatographic column: welch prep C18, 5 μm 30*250 mm; mobile phase: aqueous phase (10 mM ammonium bicarbonate) and acetonitrile, gradient ratio: aqueous phase 45%-65%) to obtain the title compound 2 (54 mg, yield: 43.84%).
[0358] MS m / z(ESI):475.0[M+1]
[0359] 1 H NMR (500MHz, DMSO-d6): δ13.65(br,1H),10.19(br,1H),8.87-8.82(m,2H),8.60(s,1H),8.34-8.25(m ,2H),8.08-8.02(m,1H),7.96-7.95(m,1H),7.57-7.55(m,1H),5.14(s,1H),2.51(s,3H),1.56(s,6H).
[0360] Example 3
[0361] 2-(4-(3-(6-((3-chloro-5-fluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 3
[0362]
[0363]
[0364] first step
[0365] N-(3-chloro-5-fluoropyridin-2-yl)-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine 3b
[0366] 3-Chloro-5-fluoropyridin-2-amine 3a (129 mg, 0.88 mmol) was dissolved in N,N-dimethylformamide (3 mL, Adamas), cooled to 0°C under nitrogen protection, added with lithium bistrimethylsilylamide (1 M, 1.10 mL, 1.10 mmol Adamas), reacted at 0°C for 0.5 hours, and added with compound 1c (300 mg, 0.73 mmol). The mixture was reacted at room temperature for 1 hour, and 20 mL of saturated ammonium chloride solution was added. The mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system C to obtain the title compound 3b (230 mg, yield: 60.5%). MS m / z (ESI): 521.4 [M+1]
[0367] Step 2
[0368] 2-(4-(3-(6-((3-chloro-5-fluoropyridin-2-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[2-(trimethylsilyl)ethoxy)methyl]
[0369] [3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 3c
[0370] Compound 3b (115 mg, 0.22 mmol) was dissolved in 1,4-dioxane (1 mL, Adamas) and water (0.1 mL), and compound 1h (95 mg, 0.27 mmol), cesium carbonate (216 mg, 0.66 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (17 mg, 0.02 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filtered, the filtrate was concentrated under reduced pressure to obtain the title compound 3c (130 mg, yield: 94.8%).
[0371] MS m / z(ESI):621.0[M+1]
[0372] Step 3
[0373] 2-(4-(3-(6-((3-chloro-5-fluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 3
[0374] Compound 3c (130 mg, 0.21 mmol) was dissolved in dichloromethane (1 mL, Sinopharm), trifluoroacetic acid (1.54 g, 13.51 mmol, Adamas) was added, and the mixture was reacted at room temperature for 3 hours. The mixture was concentrated under reduced pressure, 5 mL of saturated sodium bicarbonate was added, and the mixture was extracted with ethyl acetate (5 mL×3). The organic phases were combined, washed with 5 mL of saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system A to obtain the title compound 3 (38 mg, yield: 37.0%).
[0375] MS m / z(ESI):490.9[M+1]
[0376] 1 H NMR (500MHz, DMSO-d6): δ13.58(s,1H),9.98(s,1H),9.01(s,1H),8.86-8.85(m,1H),8.51-8.48(m,2H),8.30- 8.28(m,1H),8.05-8.04(m,1H),7.60-7.58(m,1H),5.34-5.32(m,1H),5.15(s,1H),2.51(s,3H),1.56(s,6H).
[0377] Example 4
[0378] 2-(4-(3-(6-((3-chloropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidine-2-yl
[0379] 4-(2-Methyl)propan-2-ol
[0380]
[0381] first step
[0382] N-(3-chloropyridin-2-yl)-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine 4b
[0383] 3-Chloropyridin-2-amine 4a (76 mg, 0.59 mmol) was dissolved in N,N-dimethylformamide (2 mL, Adamas), cooled to 0°C under nitrogen protection, added with lithium bistrimethylsilylamide (1 M, 0.74 mL, 0.74 mmol Adamas), reacted at 0°C for 0.5 hours, and added with compound 1c (200 mg, 0.49 mmol). The mixture was reacted at room temperature for 1 hour, and 20 mL of saturated ammonium chloride solution was added, extracted with ethyl acetate (20 mL×3), the organic phases were combined, washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system C to obtain the title compound 4b (160 mg, yield: 65.3%).
[0384] MS m / z(ESI):503.4[M+1]
[0385] Step 2
[0386] 2-(4-(3-(6-((3-chloropyridin-2-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[2-(trimethylsilyl)ethoxy)methyl]
[0387] [3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 4c
[0388] Compound 4b (80 mg, 0.16 mmol) was dissolved in 1,4-dioxane (1 mL, Adamas) and water (0.1 mL), and compound 1h (68 mg, 0.19 mmol), cesium carbonate (156 mg, 0.48 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (12 mg, 0.02 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filtered, the filtrate was concentrated under reduced pressure to obtain the title compound 4c (95 mg, yield: 99.0%).
[0389] MS m / z(ESI):603.0[M+1]
[0390] Step 3
[0391] 2-(4-(3-(6-((3-chloropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidine-2-yl
[0392] 4-(2-(4-yl)propan-2-ol
[0393] Compound 4c (95 mg, 0.16 mmol) was dissolved in dichloromethane (1 mL, Sinopharm), trifluoroacetic acid (1.54 g, 13.51 mmol, Adamas) was added, and the mixture was reacted at room temperature for 3 hours. The mixture was concentrated under reduced pressure, 5 mL of saturated sodium bicarbonate was added, and the mixture was extracted with ethyl acetate (5 mL×3). The organic phases were combined, washed with 5 mL of saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system A to obtain the title compound 4 (33 mg, yield: 44.3%).
[0394] MS m / z(ESI):472.9[M+1]
[0395] 1 H NMR (500MHz, DMSO-d6): δ13.58(s,1H),9.89(s,1H),9.01(s,1H),8.86-8.85(m,1H),8.51-8.48(m,2H),8.30- 8.28(m,1H),8.05-8.01(m,2H),7.60-7.58(m,1H),5.34-5.32(m,1H),5.15(s,1H),2.51(s,3H),1.56(s,6H).
[0396] Example 5
[0397] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluoro-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 5
[0398]
[0399] first step
[0400] 3-Bromo-2-fluoro-4-methylbenzoic acid 5b
[0401] Dissolve 2-bromo-1-fluoro-3-toluene 5a (2.0 g, 10.58 mmol, Haohong Pharmaceutical) in tetrahydrofuran (20 mL, Adamas), add lithium diisopropylamide (5.83 mL, 11.67 mmol, Adamas) under stirring at -78 ° C, and continue stirring for 1 hour. Add excess solid dry ice to the reaction solution and continue stirring for 30 minutes. Add 10 mL of water to the reaction solution to quench, extract with ethyl acetate (10 mL × 2), and adjust the pH of the aqueous phase to 2-3 with 2N hydrochloric acid. Extract with dichloromethane (10 mL × 3), combine the dichloromethane phases, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain the title compound 5b (1.0 g, yield: 40.6%).
[0402] MS m / z(ESI):233.1[M+1]
[0403] Step 2
[0404] 3-Bromo-2-fluoro-N-methoxy-N,4-dimethylbenzamide 5c
[0405] Compound 5b (1.0 g, 4.29 mmol) was dissolved in N,N-dimethylformamide (10 mL, Adamas), and dimethylhydroxylamine hydrochloride (544 mg, 5.58 mmol, Shaoyuan), O-(7-azabenzotriazole-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (2.1 g, 5.52 mmol, Shaoyuan) and N,N-diisopropylethylamine (1.1 g, 8.51 mmol, Adamas) were added in sequence. The mixture was reacted at room temperature for 2 hours, 20 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system C to obtain the title compound 5c (830 mg, yield: 70.1%).
[0406] MS m / z(ESI):276.1[M+1]
[0407] Step 3
[0408] 1-(3-Bromo-2-fluoro-4-methylphenyl)ethan-1-one 5d
[0409] Compound 5c (830 mg, 3.01 mmol) was dissolved in tetrahydrofuran (10 mL, Adamas), methylmagnesium bromide (1 M, 4.5 mL, Adamas) was added at 0°C, and the mixture was naturally warmed to room temperature for 2 hours. 20 mL of saturated ammonium chloride solution was added, and the mixture was extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system C to obtain the title compound 5d (650 mg, yield: 93.6%).
[0410] MS m / z(ESI):231.1[M+1]
[0411] Step 4
[0412] (E)-1-(3-Bromo-2-fluoro-4-methylphenyl)-3-(dimethylamino)prop-2-en-1-one 5e
[0413] Compound 5d (650 mg, 2.81 mmol) was dissolved in N,N-dimethylformamide (8 mL, Adamas), and N,N-dimethylformamide dimethyl acetal (3.4 g, 28.11 mmol Shaoyuan) was added, and the mixture was heated to 85°C and reacted overnight. 30 mL of water was added, and the mixture was extracted with dichloromethane (30 mL × 3), the organic phases were combined, washed with 20 mL of water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the title compound 5e (804 mg, yield: 99.9%). MS m / z (ESI): 286.1 [M+1]
[0414] Step 5
[0415] 2-(4-(3-Bromo-2-fluoro-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 5f
[0416] Compound 5e (804 mg, 2.81 mmol) was dissolved in N,N-dimethylformamide (10 mL, Adamas), potassium carbonate (777 mg, 5.62 mmol, Guoyao), 2-hydroxy-2-methylpropionamidine hydrochloride (778 mg, 5.61 mmol, Aikang) were added, and the mixture was heated to 65°C for 24 hours. 30 mL of water was added, and the mixture was extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with 20 mL of water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system C to obtain the title compound 5f (560 mg, yield: 61.3%). MS m / z (ESI): 325.2 [M+1]
[0417] Step 6
[0418] 2-(4-(2-fluoro-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-yl)propan-2-yl
[0419] Alcohol 5g
[0420] Compound 5f (560 mg, 1.72 mmol) was dissolved in 1,4-dioxane (8 mL, Adamas), and bis-pinacol diborane (1.1 g, 4.33 mmol Shaoyuan), potassium acetate (676 mg, 6.89 mmol Guoyao), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (126 mg, 0.17 mmol Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 1.5 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by column chromatography with eluent system C to obtain the title compound 5g (450 mg, yield: 70.2%).
[0421] MS m / z(ESI):373.2[M+1]
[0422] Step 7
[0423] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluoro-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 5h
[0424] Compound 1d (120 mg, 0.24 mmol) was dissolved in 1,4-dioxane (1 mL, Adamas) and water (0.2 mL), and compound 5g (90 mg, 0.24 mmol), cesium carbonate (232 mg, 0.71 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (18 mg, 0.02 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filtered, the filtrate was concentrated under reduced pressure to obtain the title compound 5h (145 mg, yield: 97.8%).
[0425] MS m / z(ESI):623.2[M+1]
[0426] Step 8
[0427] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluoro-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 5
[0428] Compound 5h (145 mg, 0.24 mmol) was dissolved in dichloromethane (1 mL, Sinopharm), trifluoroacetic acid (265 mg, 2.32 mmol, Adamas) was added, and the mixture was reacted at room temperature for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography with eluent system A to obtain the title compound 5 (8.2 mg, yield: 7.1%).
[0429] MS m / z(ESI):493.2[M+1]
[0430] 1 H NMR (500MHz, DMSO-d6): δ13.65(s,1H),10.02(s,1H),8.95-8.94(m,1H),8.89-8.88(m,1H),8.37-8.36(m,1H),8. 25-8.22(m,1H),8.06-8.04(m,1H),7.84-7.82(m,1H),7.46-7.44(m,1H),5.14(s,1H),2.37(s,3H),1.57(s,6H).
[0431] Example 6
[0432] 2-(4-(3-(6-((3-chloro-5-fluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluoro-4-
[0433] methylphenyl)pyrimidin-2-yl)propan-2-ol 6
[0434]
[0435]
[0436] first step
[0437] N-(3-chloro-5-fluoropyridin-2-yl)-4-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine 6b
[0438] 2-Amino-3-chloro-5-fluoropyridine (208 mg, 1.42 mmol, Bidler) was dissolved in tetrahydrofuran (4 mL, Adamas), the reaction solution was cooled to 0°C, sodium hydride (71 mg, 1.77 mmol, purity 60%) was added, and stirring was continued for half an hour. 6-Chloro-4-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine 6a (300 mg, 1.19 mmol, prepared by the method disclosed in intermediate example 3 on page 95 of the specification of patent application WO2014140065) was added, the temperature was raised to 75°C for reaction for 30 minutes, 10 mL of saturated ammonium chloride solution was added to quench, and ethyl acetate (10 mL×3) was used for extraction. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography with eluent system C to obtain the title compound 6b (260 mg, yield: 60.4%).
[0439] MS m / z(ESI):363.2[M+1]
[0440] Step 2
[0441] N-(3-Chloro-5-fluoropyridin-2-yl)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine 6c
[0442] Compound 6b (260 mg, 0.72 mmol) was dissolved in ethyl acetate (2 mL, Sinopharm), and dioxane hydrochloride (1.8 mL, 4 M, Adamas) was added at room temperature and stirred for 2 hours. The reaction solution was concentrated under reduced pressure, 3 mL of saturated sodium bicarbonate solution was added, and extracted with dichloromethane (3 mL×3), the organic phases were combined, washed with 5 mL of saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the title compound 6c (199 mg, yield: 99.6%).
[0443] MS m / z(ESI):279.1[M+1]
[0444] Step 3
[0445] N-(3-chloro-5-fluoropyridin-2-yl)-3-iodo-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine 6d
[0446] Compound 6c (199 mg, 0.71 mmol) was dissolved in N,N-dimethylformamide (3 mL, Adamas), and N-iodosuccinimide (240 mg, 1.07 mmol, Shaoyuan) was added under stirring at room temperature, and the oil bath was heated to 80°C and stirred for 2 hours. The mixture was cooled to room temperature, diluted with 10 mL of water, extracted with ethyl acetate (10 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phases were concentrated. The residue was purified by column chromatography with eluent system C to obtain the title compound 6d (288 mg, yield: 99.7%).
[0447] MS m / z(ESI):404.9[M+1]
[0448] Step 4
[0449] N-(3-chloro-5-fluoropyridin-2-yl)-3-iodo-4-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine
[0450] -6-Amine 6e
[0451] Compound 6d (288 mg, 0.71 mmol) was dissolved in tetrahydrofuran (5 mL, Adamas), 3,4-dihydro-2H-pyran (89 mg, 1.06 mmol, Adamas) and p-toluenesulfonic acid (13 mg, 0.07 mmol, Sinopharm) were added at room temperature, and stirred at 55°C for 3 hours. The reaction solution was diluted with water and extracted with ethyl acetate. The organic phase was concentrated, and the residue was purified by column chromatography with eluent system C to obtain the title compound 6e (120 mg, yield: 34.5%). MS m / z (ESI): 489.1 [M+1]
[0452] Step 5
[0453] 2-(4-(3-(6-((3-chloro-5-fluoropyridin-2-yl)amino)-4-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[2-yl]-
[0454] [3,4-d]pyrimidin-3-yl)-2-fluoro-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 6f
[0455] Compound 6e (60 mg, 0.12 mmol) was dissolved in 1,4-dioxane (1 mL, Adamas) and water (0.2 mL), and compound 5g (59 mg, 0.16 mmol), cesium carbonate (120 mg, 0.37 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (10 mg, 0.01 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filtered, the filtrate was concentrated under reduced pressure to obtain the title compound 6f (74 mg, yield: 99.3%).
[0456] MS m / z(ESI):607.2[M+1]
[0457] Step 6
[0458] 2-(4-(3-(6-((3-chloro-5-fluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluoro-4-
[0459] methylphenyl)pyrimidin-2-yl)propan-2-ol 6
[0460] Compound 6f (74 mg, 0.12 mmol) was dissolved in ethyl acetate (1 mL, Sinopharm), and a hydrogen chloride dioxane solution (0.3 mL, 4 M, Adamas) was added at room temperature and stirred for 2 hours. The mixture was concentrated under reduced pressure, 3 mL of saturated sodium bicarbonate solution was added, and the mixture was extracted with dichloromethane (3 mL×3). The organic phases were combined, washed with 5 mL of saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system A to obtain the title compound 6 (5.8 mg, yield: 9.1%).
[0461] MS m / z(ESI):523.1[M+1]
[0462] 1H NMR (500MHz, DMSO-d6): δ13.60(s,1H),9.82(s,1H),8.89-8.87(m,1H),8.49-8.48(m,1H),8.33-8.29( m,1H),8.21-8.19(m,1H),7.78-7.77(m,1H),7.47-7.45(m,1H),5.16(s,1H),2.41(s,6H),1.57(s,6H).
[0463] Example 7
[0464] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 7
[0465]
[0466] first step
[0467] N-(3,5-difluoropyridin-2-yl)-4-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine 7a
[0468] 2-Amino-3,5-difluoropyridine (422 mg, 3.24 mmol, Bid) was dissolved in tetrahydrofuran (10 mL, Adamas), the reaction solution was cooled to 0°C, sodium hydride (194 mg, 4.85 mmol, purity 60%) was added, and stirring was continued for half an hour. Compound 6a (820 mg, 3.24 mmol) was added, the temperature was raised to 75°C for reaction for 30 minutes, 20 mL of saturated ammonium chloride solution was added to quench, ethyl acetate (20 mL×3) was used for extraction, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the organic phase was concentrated, and the residue was purified by column chromatography with eluent system C to obtain the title compound 7a (430 mg, yield: 3.82%).
[0469] MS m / z(ESI):347.1[M+1]
[0470] Step 2
[0471] N-(3,5-difluoropyridin-2-yl)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine 7b
[0472] Compound 7a (430 mg, 1.24 mmol) was dissolved in ethyl acetate (2 mL, Sinopharm), and a hydrogen chloride dioxane solution (3.1 mL, 4 M, Adamas) was added at room temperature, and stirred for 2 hours. The mixture was concentrated under reduced pressure, 5 mL of saturated sodium bicarbonate solution was added, and the mixture was extracted with dichloromethane (8 mL×3). The organic phases were combined, washed with 6 mL of saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the title compound 7b (320 mg, yield: 98.3%).
[0473] MS m / z(ESI):263.2[M+1]
[0474] Step 3
[0475] N-(3,5-difluoropyridin-2-yl)-3-iodo-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine 7c
[0476] Compound 7b (320 mg, 1.22 mmol) was dissolved in N,N-dimethylformamide (5 mL, Adamas), and N-iodosuccinimide (412 mg, 1.83 mmol, Shaoyuan) was added under stirring at room temperature, and the oil bath was heated to 80°C and stirred for 2 hours. The mixture was cooled to room temperature, diluted with 10 mL of water, extracted with ethyl acetate (10 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phases were concentrated. The residue was purified by column chromatography with eluent system C to obtain the title compound 7c (473 mg, yield: 99.8%).
[0477] MS m / z(ESI):389.1[M+1]
[0478] Step 4
[0479] N-(3,5-difluoropyridin-2-yl)-3-iodo-4-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine
[0480] -6-Amine 7d
[0481] Compound 7c (473 mg, 1.22 mmol) was dissolved in tetrahydrofuran (5 mL, Adamas), 3,4-dihydro-2H-pyran (154 mg, 1.83 mmol, Adamas) and p-toluenesulfonic acid (22 mg, 0.13 mmol, Sinopharm) were added at room temperature, and stirred at 55°C for 3 hours. The reaction solution was diluted with water and extracted with ethyl acetate. The organic phase was concentrated and the residue was purified by column chromatography with eluent system C to obtain the title compound 7d (260 mg, yield: 45.2%). MS m / z (ESI): 473.2 [M+1]
[0482] Step 5
[0483] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1-(tetrahydro-2H-pyran-2-yl)amino)-1H-pyrazolo[2-(4-(
[0484] [3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 7e
[0485] Compound 7d (130 mg, 0.28 mmol) was dissolved in 1,4-dioxane (2 mL, Adamas) and water (0.4 mL), and compound 1h (108 mg, 0.31 mmol), cesium carbonate (269 mg, 0.83 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (20 mg, 0.02 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filtered, the filtrate was concentrated under reduced pressure to obtain the title compound 7e (157 mg, yield: 99.6%).
[0486] MS m / z(ESI):573.2[M+1]
[0487] Step 6
[0488] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 7
[0489] Compound 7e (157 mg, 0.27 mmol) was dissolved in ethyl acetate (2 mL, Sinopharm), and a hydrogen chloride dioxane solution (0.7 mL, 4 M, Adamas) was added at room temperature, and stirred for 2 hours. The mixture was concentrated under reduced pressure, 3 mL of saturated sodium bicarbonate solution was added, and the mixture was extracted with dichloromethane (3 mL×3). The organic phases were combined, washed with 5 mL of saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system A to obtain the title compound 7 (75 mg, yield: 55.9%).
[0490] MS m / z(ESI):489.2[M+1]
[0491] 1 H NMR (500MHz, DMSO-d6): δ13.58(s,1H),9.85(s,1H),8.44-8.43(m,1H),8.36-8.33(m,3H), 8.04-8.01(m,2H),7.58-7.56(m,1H),5.14(s,1H),2.27(s,3H),2.22(s,3H),1.54(s,6H).
[0492] Example 8
[0493] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluoro-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 8
[0494]
[0495] first step
[0496] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1-(tetrahydro-2H-pyran-2-yl)amino)-1H-pyrazolo[2-(4-(
[0497] [3,4-d]pyrimidin-3-yl)-2-fluoro-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 8a
[0498] Compound 7d (130 mg, 0.28 mmol) was dissolved in 1,4-dioxane (2 mL, Adamas) and water (0.4 mL), and compound 5g (103 mg, 0.28 mmol), cesium carbonate (269 mg, 0.83 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (20 mg, 0.02 mmol Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filtered, the filtrate was concentrated under reduced pressure to obtain the title compound 8a (162 mg, yield: 99.6%).
[0499] MS m / z(ESI):591.2[M+1]
[0500] Step 2
[0501] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluoro-4-methylphenyl)pyrimidin-2-yl)propan-2-ol 8
[0502] Compound 8a (162 mg, 0.27 mmol) was dissolved in ethyl acetate (2 mL, Sinopharm), and a hydrogen chloride dioxane solution (0.7 mL, 4 M, Adamas) was added at room temperature and stirred for 2 hours. The mixture was concentrated under reduced pressure, 3 mL of saturated sodium bicarbonate solution was added, and the mixture was extracted with dichloromethane (3 mL×3). The organic phases were combined, washed with 5 mL of saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system A to obtain the title compound 8 (31 mg, yield: 22.3%).
[0503] MS m / z(ESI):507.2[M+1]
[0504] 1 H NMR (500MHz, DMSO-d6): δ13.61(s,1H),9.91(s,1H),8.88-8.87(m,1H),8.36-8.31(m,2H),8. 05-8.03(m,1H),7.78-7.77(m,1H),7.47-7.45(m,1H),5.15(s,1H),2.22(s,6H),1.57(s,6H).
[0505] Example 9
[0506] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidine
[0507] -2-yl)-2-methylpropan-1-ol9
[0508]
[0509]
[0510] first step
[0511] 2-(4-(3-Bromo-4-methylphenyl)pyrimidin-2-yl)-2-methylpropan-1-ol 9a
[0512] Compound 1f (1.1 g, 4.1 mmol) was dissolved in N, N-dimethylformamide (60 mL, Adamas), potassium carbonate (1.47 g, 10.7 mmol Chinese medicine), 3-hydroxy-2,2-dimethylpropionimide (1.43 g, 12.3 mmol, prepared by the method disclosed in intermediate 00307 on page 118 of the specification of patent application WO2022212489A1), and heated to 80 ° C for 24 hours. 100 mL of water was added, extracted with dichloromethane (100 mL × 3), the organic phases were combined, washed with 100 mL of water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system C to obtain the title compound 9a (270 mg, yield: 20.5%). MS m / z (ESI): 321.0 [M+1]
[0513] Step 2
[0514] 2-Methyl-2-(4-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-yl)propane
[0515] -1-ol 9b
[0516] Compound 9a (100 mg, 0.3 mmol) was dissolved in 1,4-dioxane (3 mL, Adamas), and bis-pinacol diborane (198 mg, 0.78 mmol, Shaoyuan), potassium acetate (122 mg, 1.24 mmol, Sinopharm), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (26 mg, 0.03 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 12 hours. Filter, concentrate the filtrate under reduced pressure, and purify the residue by column chromatography with eluent system C to obtain the title compound 9b (110 mg, yield: 95.9%).
[0517] MS m / z(ESI):369.3[M+1]
[0518] Step 3
[0519] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[2-(trimethylsilyl)ethoxy)methyl]
[0520] [3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidin-2-yl)-2-methylpropan-1-ol 9c
[0521] Compound 1d (150 mg, 0.3 mmol) was dissolved in 1,4-dioxane (2 mL, Adamas) and water (0.2 mL), and compound 9b (110 mg, 0.3 mmol), cesium carbonate (291 mg, 0.89 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (22 mg, 0.03 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 5 hours. Filtered, the filtrate was concentrated under reduced pressure to obtain the title compound 9c (155 mg, yield: 84.2%).
[0522] MS m / z(ESI):619.0[M+1]
[0523] Step 4
[0524] 2-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidine
[0525] -2-yl)-2-methylpropan-1-ol9
[0526] Compound 9c (120 mg, 0.2 mmol) was dissolved in dichloromethane (2 mL, Sinopharm), trifluoroacetic acid (3.1 g, 27 mmol Adamas) was added, and the mixture was reacted at room temperature for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography using eluent system A to obtain the title compound 9 (30 mg, yield: 31.7%).
[0527] MS m / z(ESI):489.5[M+1]
[0528] 1 H NMR (500MHz, DMSO-d6): δ10.02(s,2H),9.02(s,1H),8.80(d,1H),8.45(d,1H),8.37(d,1H),8.22(d,1 H),8.06-8.02(m,1H),7.95(d,1H),7.58(d,1H),4.59(t,1H),3.72(d,2H),2.53(s,3H),1.35(s,6H).
[0529] Example 10
[0530] 1-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidine
[0531] -2-yl)cyclopentan-1-ol 10
[0532]
[0533]
[0534] first step
[0535] 1-(4-(3-Bromo-4-methylphenyl)pyrimidin-2-yl)cyclopentan-1-ol 10a
[0536] Compound 1f (400 mg, 1.49 mmol) was dissolved in N,N-dimethylformamide (18 mL, Adamas), potassium carbonate (536 mg, 3.88 mmol, Chinese medicine), 1-hydroxycyclopentane-1-carboximide (574 mg, 4.48 mmol, prepared by the method disclosed in the intermediate 0338 on page 60 of the specification of patent application CN116354935A), heated to 80 ° C for 24 hours. 30 mL of water was added, extracted with dichloromethane (30 mL × 3), the organic phases were combined, washed with 30 mL of water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system C to obtain the title compound 10a (110 mg, yield: 22.13%). MS m / z (ESI): 333.0 [M+1]
[0537] Step 2
[0538] 1-(4-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-yl)cyclopentan-1-ol 10b
[0539] Compound 10a (50 mg, 0.15 mmol) was dissolved in 1,4-dioxane (2 mL, Adamas), and bis-pinacol diborane (95 mg, 0.37 mmol, Shaoyuan), potassium acetate (59 mg, 0.6 mmol, Sinopharm), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (13 mg, 0.02 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 12 hours. Filter, concentrate the filtrate under reduced pressure, and purify the residue by column chromatography with eluent system C to obtain the title compound 10b (52 mg, yield: 91.13%).
[0540] MS m / z(ESI):381.3[M+1]
[0541] Step 3
[0542] 1-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[2-(trimethylsilyl)ethoxy)methyl]
[0543] [3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidin-2-yl)cyclopentan-1-ol 10c
[0544] Compound 1d (70 mg, 0.14 mmol) was dissolved in 1,4-dioxane (2 mL, Adamas) and water (0.2 mL), and compound 10b (52.8 mg, 0.14 mmol), cesium carbonate (136 mg, 0.42 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (10 mg, 0.01 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 5 hours. Filtered, the filtrate was concentrated under reduced pressure to obtain the title compound 10c (50 mg, yield: 57.11%).
[0545] MS m / z(ESI):631.0[M+1]
[0546] Step 4
[0547] 1-(4-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyrimidine
[0548] -2-yl)cyclopentan-1-ol 10
[0549] Compound 10c (50 mg, 0.08 mmol) was dissolved in dichloromethane (1 mL, Sinopharm), trifluoroacetic acid (1.54 g, 13.5 mmol, Adamas) was added, and the mixture was reacted at room temperature for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography using eluent system A to obtain the title compound 10 (5 mg, yield: 12.6%).
[0550] MS m / z(ESI):501.6[M+1]
[0551] 1 H NMR (500MHz, DMSO-d6): δ9.97(s,2H),8.99(s,1H),8.84(d,1H),8.47(d,1H),8.35(d,1H),8.26( d,1H),8.05-8.02(m,2H),7.57(d,1H),5.10(s,1H),3.23-3.20(m,3H),1.89(s,4H),1.24(s,4H).
[0552] Embodiment 11
[0553] 2-(4-(4-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-3-yl)-5-methylpyridin-2-yl)pyrimidin-2-yl)propan-2-ol 11
[0554]
[0555] first step
[0556] 2-(4-(4-(6-((3,5-difluoropyridin-2-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-5-methylpyridin-2-yl)pyrimidin-2-yl)propan-2-ol 11c
[0557] N-(3,5-difluoropyridin-2-yl)-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridin-6-amine 11a (90 mg, 0.18 mmol, prepared by using the synthetic route 1d in Example 1, replacing 1a with 6-chloro-1H-pyrazolo[3,4-b]pyridine) was dissolved in 1,4-dioxane (3 mL, Adamas) and water (0.5 mL), and 2-(4-(5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxane)) was added. Heteropentalborane-2-yl)pyridin-2-yl)pyrimidin-2-yl)propan-2-ol 11b (64 mg, 0.18 mmol, prepared by the method disclosed in the intermediate intermadiate 22 on page 98 of the specification of patent application WO2022212489A1), cesium carbonate (175 mg, 0.54 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (14 mg, 0.02 mmol Adamas), nitrogen replacement 3 times, heated to 100 ° C for 3 hours. Filter, concentrate the filtrate under reduced pressure, and purify the residue by column chromatography with eluent system A to obtain the title compound 11c (85 mg, yield: 78.6%).
[0558] MS m / z(ESI):605.0[M+1]
[0559] Step 2
[0560] 2-(4-(4-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-3-yl)-5-methylpyridin-2-yl)pyrimidin-2-yl)propan-2-ol 11
[0561] Compound 11c (85 mg, 0.14 mmol, Shaoyuan) was dissolved in dichloromethane (5 mL, Adamas), trifluoroacetic acid (162 mg, 1.40 mmol, Adamas) was added, and the mixture was reacted at room temperature for 3 hours. The reaction solution was concentrated, and the residue was added with 10 mL of saturated sodium bicarbonate aqueous solution, extracted with ethyl acetate (10 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phases were concentrated. The residue was purified by column chromatography with eluent system C to obtain the title compound 11 (20 mg, yield: 30.0%).
[0562] MS m / z(ESI):475.0[M+1]
[0563] 1 H NMR (500MHz, DMSO-d6): δ9.71(s,1H),8.97-8.96(m,1H),8.81-8.77(m,2H),8.31-8.26(m,2H),8.12-8 .11(m,1H),8.02-8.01(m,1H),7.24-7.22(m,1H),5.22(s,1H),3.32(s,1H),2.55(s,3H),1.57(s,6H).
[0564] Example 12
[0565] 2-(4-(4-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-methylpyridin-2-yl)pyrimidin-2-yl)propan-2-ol 12
[0566]
[0567]
[0568] first step
[0569] N-(3,5-difluoropyridin-2-yl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-6-amine 12a
[0570] Compound 1d (613 mg, 1.21 mmol, Shaoyuan) was dissolved in dichloromethane (10 mL, Adamas), trifluoroacetic acid (1.4 g, 12.28 mmol, Adamas) was added, and the mixture was reacted at room temperature for 3 hours. The reaction solution was concentrated, and the residue was added with 10 mL of saturated sodium bicarbonate aqueous solution, extracted with ethyl acetate (10 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phases were concentrated. The residue was purified by column chromatography with eluent system C to obtain the title compound 12a (140 mg, yield: 30.8%).
[0571] MS m / z(ESI):375.1[M+1]
[0572] Step 2
[0573] 2-(4-(4-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-methylpyridin-2-yl)pyrimidin-2-yl)propan-2-ol 12
[0574] Compound 12a (140 mg, 0.37 mmol) was dissolved in 1,4-dioxane (3 mL, Adamas) and water (0.5 mL), and 2-(4-(5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)pyridin-2-yl)pyrimidin-2-yl)propan-2-ol 11b (160 mg, 0.45 mmol), cesium carbonate (366 mg, 1.12 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (28 mg, 0.03 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filter, concentrate the filtrate under reduced pressure, and purify the residue by column chromatography with eluent system A to obtain the title compound 12 (8 mg, yield: 4.5%).
[0575] MS m / z(ESI):476.2[M+1]
[0576] 1 H NMR (500MHz, DMSO-d6): δ13.85(s,1H),10.11(s,1H),9.13(s,1H),8.97-8.96(m,1H),8.86-8.79(m, 2H),8.38-8.36(m,1H),8.26-8.25(m,1H),8.08-8.04(m,1H),5.27(s,1H),2.51(s,3H),1.57(s,6H).
[0577] Embodiment 13
[0578] 2-(4-(4-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-methylpyridin-2-yl)pyrimidin-2-yl)propan-2-ol 13
[0579]
[0580] first step
[0581] 2-(4-(4-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-methylpyridin-2-yl)pyrimidin-2-yl)propan-2-ol 13
[0582] Compound 7c (120 mg, 0.31 mmol) was dissolved in 1,4-dioxane (3 mL, Adamas) and water (0.5 mL), and compound 12b (110 mg, 0.31 mmol), cesium carbonate (302 mg, 0.93 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (23 mg, 0.03 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filter, concentrate the filtrate under reduced pressure, and purify the residue by column chromatography with eluent system A to obtain the title compound 13 (22 mg, yield: 14.5%).
[0583] MS m / z(ESI):490.2[M+1]
[0584] 1 H NMR (500MHz, DMSO-d6): δ13.62(s,1H),9.93(s,1H),8.96-8.95(m,1H),8.79-8.77(m,2H),8.37-8.3 6(m,1H),8.27-8.26(m,1H),8.05-8.01(m,1H),5.25(s,1H),2.36(s,3H),2.30(s,3H),1.57(s,6H).
[0585] Embodiment 14
[0586] 4'-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-(2-hydroxypropan-2-yl)-5'-
[0587] Methoxy-2H-[1,2'-bipyridyl]-2-one 14
[0588]
[0589] first step
[0590] 2-Bromo-4-iodo-5-methoxypyridine 14b
[0591] 2-Bromo-5-fluoro-4-iodopyridine 14a (3 g, 9.94 mmol, Leyan) was dissolved in methanol (40 mL, Adamas), sodium methoxide (1.6 g, 29.61 mmol, Adamas) was added under ice bath, and stirred at room temperature for 2 days. The reaction solution was cooled and concentrated, and the residue was purified by column chromatography with eluent system C to obtain the title compound 14b (600 mg, yield: 19.2%).
[0592] MS m / z(ESI):313.9[M+1]
[0593] Step 2
[0594] 3-(2-Hydroxypropan-2-yl)-4'-iodo-5'-methoxy-2H-[1,2'-bipyridyl]-2-one 14c
[0595] Compound 14b (1 g, 3.18 mmol), 3-(2-hydroxypropan-2-yl)pyridin-2(1H)-one (500 mg, 3.26 mmol, prepared by the method disclosed for intermediate intermadiate 1 on page 46 of the specification of patent application WO2023283338A1), cuprous iodide (63 mg, 0.33 mmol, Adamas), N,N'-dimethylethylenediamine (29 mg, 0.33 mmol, Shaoyuan) and potassium carbonate (903 mg, 6.53 mmol, Sinopharm) were placed in 1,4-dioxane (10 mL, Adamas), replaced with nitrogen three times, and stirred at 100°C overnight. 20 mL of water was added to the reaction solution, extracted with ethyl acetate (15 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated. The residue was purified by column chromatography with eluent system C to give the title compound 14c (590 mg, yield: 46.8%).
[0596] MS m / z(ESI):387.1[M+1]
[0597] Step 3
[0598] 3-(2-Hydroxypropan-2-yl)-5'-methoxy-4'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-[1,2'-
[0599] Bipyridyl]-2-one 14d
[0600] Compound 14c (590 mg, 1.52 mmol) was dissolved in 1,4-dioxane (10 mL, Adamas), and bis-pinacol diborane (1.5 g, 6.10 mmol, Shaoyuan), potassium acetate (375 mg, 3.82 mmol, Sinopharm), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (112 mg, 0.15 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C to react overnight. The reaction solution was concentrated, and the residue was purified by column chromatography with eluent system C to obtain the title compound 14d (550 mg, yield: 93.2%).
[0601] MS m / z(ESI):387.2[M+1]
[0602] Step 4
[0603] 4'-(6-((3,5-difluoropyridin-2-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-d]
[0604] Pyrimidin-3-yl)-3-(2-hydroxypropan-2-yl)-5'-methoxy-2H-[1,2'-bipyridyl]-2-one 14e
[0605] Compound 1d (120 mg, 0.24 mmol) was dissolved in 1,4-dioxane (1.5 mL, Adamas), water (0.3 mL), compound 14d (120 mg, 0.31 mmol), cesium carbonate (232 mg, 0.71 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (18 mg, 0.02 mmol, Adamas), nitrogen was replaced 3 times, heated to 100°C for 3 hours, filtered, and the filtrate was concentrated under reduced pressure to obtain the title compound 14e (151 mg, yield: 99.6%).
[0606] MS m / z(ESI):637.2[M+1]
[0607] Step 5
[0608] 4'-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-(2-hydroxypropan-2-yl)-5'-
[0609] Methoxy-2H-[1,2'-bipyridyl]-2-one 14
[0610] Compound 14e (151 mg, 0.24 mmol) was dissolved in tetrahydrofuran (1 mL, Adamas), tetrabutylammonium fluoride (4.4 mL, 1 M, Adamas) was added, and the mixture was reacted at 100°C overnight. 10 mL of water was added to the reaction solution, and the mixture was extracted with ethyl acetate (8 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography with eluent system A to obtain the title compound 14 (6 mg, yield: 4.9%). MS m / z (ESI): 507.2 [M+1]
[0611] 1H NMR (500MHz, DMSO-d6): δ13.61(s,1H),10.01(s,1H),8.55-8.53(m,1H),8.37-8.36(m,1H),8.06-8.00(m,2H),7. 78-7.76(m,1H),7.71-7.69(m,1H),6.42-6.39(m,1H),5.34(s,1H),4.10(s,3H),3.18-3.15(m,1H),1.47(s,6H).
[0612] Embodiment 15
[0613] 1-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)-3-(2-hydroxypropan-2-yl)pyridin-2(1H)-one 15
[0614]
[0615] first step
[0616] 3-(2-Hydroxypropan-2-yl)-1-(3-iodo-4-methylphenyl)pyridin-2(1H)-one 15b
[0617] 4-Bromo-2-iodo-1-toluene 15a (400 mg, 1.34 mmol), 3-(2-hydroxypropan-2-yl)pyridin-2(1H)-one (250 mg, 1.63 mmol), cuprous iodide (25 mg, 0.13 mmol, Adamas), N,N'-dimethylethylenediamine (11 mg, 0.13 mmol, Shaoyuan) and potassium carbonate (372 mg, 2.69 mmol, Sinopharm) were placed in 1,4-dioxane (5 mL, Adamas), replaced with nitrogen three times, and stirred at 100°C overnight. 20 mL of water was added to the reaction solution, extracted with ethyl acetate (15 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated. The residue was purified by column chromatography with eluent system C to obtain the title compound 15b (200 mg, yield: 46.1%).
[0618] MS m / z(ESI):370.2[M+1]
[0619] Step 2
[0620] 3-(2-Hydroxypropan-2-yl)-1-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine
[0621] -2(1H)-Keto 15c
[0622] Compound 15b (280 mg, 0.87 mmol) was dissolved in 1,4-dioxane (10 mL, Adamas), and bis-pinacol diborane (883 mg, 3.48 mmol, Shaoyuan), potassium acetate (213 mg, 2.17 mmol, Guoyao), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (64 mg, 0.08 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for overnight reaction. The reaction solution was concentrated, and the residue was purified by column chromatography with eluent system C to obtain the title compound 15c (280 mg, yield: 87.2%).
[0623] MS m / z(ESI):370.2[M+1]
[0624] Step 3
[0625] 1-(3-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)-3-(2-hydroxypropan-2-yl)pyridin-2(1H)-one 15
[0626] Compound 12a (100 mg, 0.27 mmol) was dissolved in 1,4-dioxane (1 mL, Adamas) and water (0.2 mL), and compound 15c (100 mg, 0.27 mmol), cesium carbonate (175 mg, 0.54 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (20 mg, 0.02 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filtered, concentrated under reduced pressure, and the residue was purified by column chromatography with eluent system A to obtain the title compound 15 (3.1 mg, yield: 2.4%).
[0627] MS m / z(ESI):490.2[M+1]
[0628] 1 H NMR (500MHz, DMSO-d6): δ13.61(s,1H),9.99(s,1H),9.01(s,1H),8.36-8.35(m,1H),8.05-8.00(m,1H),7.72- 7.70(m,3H),7.68-7.66(m,1H),7.42-7.36(m,1H),6.39-6.36(m,1H),5.34(s,1H),2.49(s,3H),1.47(s,6H).
[0629] Example 16
[0630] 1-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)-3-(2-hydroxypropan-2-yl)pyridin-2(1H)-one 16
[0631]
[0632]
[0633] first step
[0634] 1-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)-3-(2-hydroxypropan-2-yl)pyridin-2(1H)-one 16
[0635] Compound 7c (60 mg, 0.15 mmol) was dissolved in 1,4-dioxane (1 mL, Adamas) and water (0.2 mL), and compound 15c (58 mg, 0.15 mmol), cesium carbonate (100 mg, 0.31 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (11 mg, 0.01 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filter, concentrate the filtrate under reduced pressure, and purify the residue by column chromatography with eluent system A to obtain the title compound 16 (3 mg, yield: 3.8%).
[0636] MS m / z(ESI):504.2[M+1]
[0637] 1 H NMR (500MHz, DMSO-d6): δ13.40(s,1H),9.84(s,1H),8.35-8.34(m,1H),8.03-7.99(m,1H),7.66-7.62(m,2H), 7.51-7.41(m,1H),7.25-7.21(m,2H),6.38-6.36(m,1H),5.34(s,1H),2.26(s,3H),2.22(s,3H),1.47(s,6H).
[0638] Embodiment 17
[0639] 1-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)-3-(prop-1-en-2-yl)pyridin-2(1H)-one 17
[0640]
[0641]
[0642] first step
[0643] 1-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]
[0644] Pyrimidin-3-yl)-4-methylphenyl)-3-(2-hydroxypropan-2-yl)pyridin-2(1H)-one 17a
[0645] Compound 7d (80 mg, 0.17 mmol) was dissolved in 1,4-dioxane (1 mL, Adamas) and water (0.1 mL), and compound 15c (63 mg, 0.17 mmol), cesium carbonate (165 mg, 0.51 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (13 mg, 0.02 mmol Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. 5 mL of water was added to the reaction solution, and it was extracted with ethyl acetate (5 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated under reduced pressure to obtain the title compound 17a (99 mg, yield: 99.4%).
[0646] MS m / z(ESI):588.2[M+1]
[0647] Step 2
[0648] 1-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)-3-(prop-1-en-2-yl)pyridin-2(1H)-one 17
[0649] Compound 17a (99 mg, 0.17 mmol) was dissolved in ethyl acetate (1 mL, Sinopharm), and a hydrogen chloride dioxane solution (0.5 mL, 4 M, Adamas) was added at room temperature and stirred for 2 hours. The mixture was concentrated under reduced pressure, 3 mL of saturated sodium bicarbonate solution was added, and the mixture was extracted with dichloromethane (3 mL×3). The organic phases were combined, washed with 5 mL of saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with eluent system A to obtain the title compound 17 (5 mg, yield: 6.1%).
[0650] MS m / z(ESI):486.2[M+1]
[0651] 1H NMR (500MHz, DMSO-d6): δ13.57(s,1H),9.99(s,1H),8.35-8.34(m,1H),8.03-8.00(m,1H),7.66-7.64(m,1H),7.53- 7.50(m,2H),7.44-7.40(m,2H),6.36-6.34(m,1H),5.85-5.84(m,1H),5.16(s,1H),2.26-2.22(m,6H),2.07(s,3H).
[0652] Embodiment 18
[0653] 1-(3-(6-((5-chloro-3-fluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)-3-(2-hydroxypropan-2-yl)pyridin-2(1H)-one 18
[0654]
[0655] first step
[0656] N-(5-chloro-3-fluoropyridin-2-yl)-4-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine 18a
[0657] 2-Amino-3-fluoro-5-chloropyridine (280 mg, 1.98 mmol, Bid) was dissolved in tetrahydrofuran (10 mL, Adamas), the reaction solution was cooled to 0°C, sodium hydride (113 mg, 2.95 mmol, purity 60%) was added, and stirring was continued for half an hour. Compound 6a (500 mg, 1.98 mmol) was added, the temperature was raised to 75°C for reaction for 30 minutes, 10 mL of saturated ammonium chloride solution was added to quench, ethyl acetate (10 mL×3) was used for extraction, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the organic phase was concentrated, and the residue was purified by column chromatography with eluent system C to obtain the title compound 18a (390 mg, yield: 54.3%).
[0658] MS m / z(ESI):363.1[M+1]
[0659] Step 2
[0660] N-(5-chloro-3-fluoropyridin-2-yl)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine 18b
[0661] Compound 18a (390 mg, 1.07 mmol) was dissolved in ethyl acetate (2 mL, Sinopharm), and a hydrogen chloride dioxane solution (2.7 mL, 4 M, Adamas) was added at room temperature, and stirred for 2 hours. The mixture was concentrated under reduced pressure, 10 mL of saturated sodium bicarbonate solution was added, and the mixture was extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with 5 mL of saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the title compound 18b (299 mg, yield: 99.8%).
[0662] MS m / z(ESI):279.2[M+1]
[0663] Step 3
[0664] N-(5-Chloro-3-fluoropyridin-2-yl)-3-iodo-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine 18c
[0665] Compound 18b (299 mg, 1.07 mmol) was dissolved in N,N-dimethylformamide (5 mL, Adamas), and N-iodosuccinimide (362 mg, 1.61 mmol, Shaoyuan) was added under stirring at room temperature, and the oil bath was heated to 80°C and stirred for 2 hours. After cooling to room temperature, 10 mL of water was added for dilution, and the mixture was extracted with ethyl acetate (10 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phases were concentrated. The residue was purified by column chromatography with eluent system C to obtain the title compound 18c (400 mg, yield: 92.1%).
[0666] MS m / z(ESI):404.9[M+1]
[0667] Step 4
[0668] 1-(3-(6-((5-chloro-3-fluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)-3-(2-hydroxypropan-2-yl)pyridin-2(1H)-one 18
[0669] Compound 18c (60 mg, 0.15 mmol) was dissolved in 1,4-dioxane (1 mL, Adamas) and water (0.1 mL), and compound 15c (55 mg, 0.15 mmol), cesium carbonate (97 mg, 0.30 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (11 mg, 0.01 mmol Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filter, concentrate the filtrate under reduced pressure, and purify the residue by column chromatography with eluent system A to obtain the title compound 18 (2.2 mg, yield: 2.8%).
[0670] MS m / z(ESI):520.2[M+1]
[0671] 1 H NMR (500MHz, DMSO-d6): δ13.46(s,1H),10.01(s,1H),8.35-8.34(m,1H),8.14-8.10(m,1H),7.66-7.60(m,2H) ,7.51-7.41(m,1H),7.25-7.21(m,2H),6.38-6.36(m,1H),5.34(s,1H),2.26(s,3H),2.22(s,3H),1.47(s,6H).
[0672] Embodiment 19
[0673] 4'-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-(2-hydroxypropan-2-yl)-5'-
[0674] Methyl-2H-[1,2'-bipyridyl]-2-one 19
[0675]
[0676]
[0677] first step
[0678] 2-Bromo-4-iodo-5-methylpyridine 19b
[0679] 2-Bromo-4-amino-5-methylpyridine 19a (3 g, 16.11 mmol, Shaoyuan) and carbon triiodide (9.5 g, 24.19 mmol, Bid) were dissolved in tetrahydrofuran (40 mL), tert-butyl nitrite (2.5 g, 24.24 mmol, Adamas) was added at 0°C, the mixture was heated to room temperature for 1 hour, and then heated to 50°C for 3 hours. 100 mL of water was added for dilution, and the mixture was extracted with ethyl acetate (50 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phases were concentrated. The residue was purified by column chromatography with eluent system C to obtain the title compound 19b (2.7 g, yield: 56.5%).
[0680] MS m / z(ESI):297.9[M+1]
[0681] Step 2
[0682] 3-(2-Hydroxypropan-2-yl)-4'-iodo-5'-methyl-2H-[1,2'-bipyridinyl]-2-one 19c
[0683] Compound 19b (1.2 g, 4.01 mmol), 3-(2-hydroxypropan-2-yl)pyridin-2(1H)-one (520 mg, 3.39 mmol), cuprous iodide (65 mg, 0.34 mmol, Adamas), N,N'-dimethylethylenediamine (30 mg, 0.34 mmol, Shaoyuan) and potassium carbonate (938 mg, 6.78 mmol, Sinopharm) were placed in 1,4-dioxane (20 mL, Adamas), replaced with nitrogen three times, and stirred at 100°C overnight. 30 mL of water was added to the reaction solution, extracted with ethyl acetate (20 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, the organic phases were concentrated, and the residue was purified by column chromatography with eluent system C to obtain the title compound 19c (730 mg, yield: 58.1%). MS m / z(ESI):371.1[M+1]
[0684] Step 3
[0685] 3-(2-Hydroxypropan-2-yl)-5'-methyl-4'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-[1,2'-bipyridyl]-2-one 19d
[0686] Compound 19c (730 mg, 1.97 mmol) was dissolved in 1,4-dioxane (10 mL, Adamas), and bis-pinacol diborane (2.0 g, 7.87 mmol, Shaoyuan), potassium acetate (483 mg, 4.92 mmol, Sinopharm), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (144 mg, 0.19 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C to react overnight. The reaction solution was concentrated, and the residue was purified by column chromatography with eluent system C to obtain the title compound 19d (460 mg, yield: 63.1%).
[0687] MS m / z(ESI):371.2[M+1]
[0688] Step 4
[0689] 4'-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-(2-hydroxypropan-2-yl)-5'-
[0690] Methyl-2H-[1,2'-bipyridyl]-2-one 19
[0691] Compound 12a (100 mg, 0.27 mmol) was dissolved in 1,4-dioxane (1 mL, Adamas) and water (0.2 mL), and compound 19d (100 mg, 0.27 mmol), cesium carbonate (175 mg, 0.54 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (20 mg, 0.02 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filter, concentrate the filtrate under reduced pressure, and purify the residue by column chromatography with eluent system A to obtain the title compound 19 (1.1 mg, yield: 0.8%).
[0692] MS m / z(ESI):491.2[M+1]
[0693] 1 H NMR (500MHz, DMSO-d6): δ13.85(s,1H),10.08(s,1H),9.16-9.14(m,1H),8.64-8.61(m,1H),8.37-8.36(m,1H),8. 05-8.02(m,2H),7.87-7.85(m,1H),7.72-7.70(m,1H),6.45-6.42(m,1H),5.33(s,1H),2.52(s,3H),1.49(s,6H).
[0694] Embodiment 20
[0695] 4'-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-(2-hydroxypropan-2-yl)amino)-
[0696] 2H-[1,2'-bipyridyl]-5'-methyl-2H-[1,2'-bipyridyl]-2-one
[0697]
[0698] first step
[0699] 2-(Trimethylsilyl)ethyl-6-((3,5-difluoropyridin-2-yl)amino)-3-iodo-4-methyl-1H-pyrazolo[3,4-d]
[0700] Pyrimidine-1-carboxylate 20a
[0701] Compound 7c (6 g, 15.45 mmol, Shaoyuan) and triethylamine (7.9 g, 78.07 mmol, Guoyao) were dissolved in 1,4-dioxane (50 mL) and water (50 mL), and N-[2-(trimethylsilyl)ethoxycarbonyloxy]succinimide (6 g, 23.21 mmol, Shaoyuan) was added and reacted at room temperature for 2 hours. 50 mL of water was added to the reaction solution, and it was extracted with ethyl acetate (50 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated. The residue was purified by column chromatography with eluent system C to obtain the title compound 20a (8 g, yield: 97.2%).
[0702] MS m / z(ESI):533.1[M+1]
[0703] Step 2
[0704] 4'-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-(2-hydroxypropan-2-yl)amino)-
[0705] 2H-[1,2'-bipyridyl]-5'-methyl-2H-[1,2'-bipyridyl]-2-one
[0706] Compound 20a (3.5 g, 6.57 mmol) was dissolved in 1,4-dioxane (60 mL, Adamas) and water (6 mL), and compound 19d (3.5 g, 9.45 mmol), cesium carbonate (2.7 g, 19.68 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (721 mg, 0.98 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filter, concentrate the filtrate under reduced pressure, and purify the residue by column chromatography with eluent system A to obtain the title compound 20 (260 mg, yield: 7.8%).
[0707] MS m / z(ESI):505.2[M+1]
[0708] 1 H NMR (500MHz, DMSO-d6): δ13.63(s,1H),9.92(s,1H),8.64-8.62(m,1H),8.36-8.34(m,1H),8.04-8.01(m,1H),7.83- 7.82(m,1H),7.78(s,1H),7.70-7.68(m,1H),6.45-6.42(m,1H),5.25(s,1H),2.34(s,3H),2.30(s,3H),1.47(s,6H).
[0709] Embodiment 21
[0710] (±)-3-(1-cyclopropyl-1-hydroxyethyl)-1-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[2-yl]-1-yl)-
[0711] [3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyridin-2(1H)-one 21
[0712]
[0713]
[0714] first step
[0715] (±)-3-(1-cyclopropyl-1-hydroxyethyl)-1-(3-iodo-4-methylphenyl)pyridin-2(1H)-one 21a
[0716] Compound 15a (991 mg, 3.33 mmol), 3-(1-cyclopropyl-1-hydroxyethyl)pyridin-2(1H)-one (500 mg, 2.79 mmol, prepared by the method disclosed in intermediate 00242 on page 78 of the specification of patent application WO2023283338A1), cuprous iodide (54 mg, 0.28 mmol, Adamas), N,N'-dimethylethylenediamine (13 mg, 0.14 mmol, Shaoyuan) and potassium carbonate (771 mg, 5.58 mmol, Sinopharm) were placed in 1,4-dioxane (10 mL, Adamas), replaced with nitrogen three times, and stirred at 100°C overnight. 30 mL of water was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography with eluent system C to give the title compound 21a (320 mg, yield: 32.9%).
[0717] MS m / z(ESI):396.1[M+1]
[0718] Step 2 (±)-3-(1-cyclopropyl-1-hydroxyethyl)-1-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridin-2(1H)-one 21b
[0719] Compound 21a (320 mg, 0.92 mmol) was dissolved in 1,4-dioxane (5 mL, Adamas), and bis-pinacol diborane (933 mg, 3.67 mmol, Shaoyuan), potassium acetate (225 mg, 2.29 mmol, Sinopharm), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (68 mg, 0.09 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C to react overnight. The reaction solution was concentrated, and the residue was purified by column chromatography with eluent system C to obtain the title compound 21b (260 mg, yield: 71.6%).
[0720] MS m / z(ESI):396.2[M+1]
[0721] Step 3
[0722] (±)-3-(1-cyclopropyl-1-hydroxyethyl)-1-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyridin-2(1H)-one 21
[0723] Compound 7c (50 mg, 0.13 mmol) was dissolved in 1,4-dioxane (1 mL, Adamas) and water (0.1 mL), and compound 21b (51 mg, 0.13 mmol), cesium carbonate (85 mg, 0.26 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (10 mg, 0.01 mmol Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filter, concentrate the filtrate under reduced pressure, and purify the residue by column chromatography with eluent system A to obtain the title compound 21 (6.8 mg, yield: 9.9%).
[0724] MS m / z(ESI):530.2[M+1]
[0725] 1 H NMR (500MHz, DMSO-d6): δ13.41(s,1H),9.85(s,1H),8.34-8.33(m,1H),8.03-7.99(m,1H),7.66-7.62(m,2H),7.44-7.36(m,3H),6.37- 6.35(m,1H),5.15(s,1H),2.26-2.24(m,6H),1.62-1.59(m,1H),1.49(s,3H),0.47-0.45(m,1H),0.28-0.26(m,2H),0.16-0.13(m,1H).
[0726] Embodiment 21-1, 21-2
[0727] (R)-3-(1-cyclopropyl-1-hydroxyethyl)-1-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyridin-2(1H)-one 21-1
[0728] (S)-3-(1-cyclopropyl-1-hydroxyethyl)-1-(3-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methylphenyl)pyridin-2(1H)-one 21-2
[0729]
[0730] Compound 21 (60 mg, 0.11 mmol) was subjected to chiral preparation (separation conditions: chiral preparation column Lux Amylose-2, 5 μm, 20 mm*250 mm (Phenomenex), SN: H15-243270; mobile phase: n-hexane:ethanol=60:40 (v / v), flow rate: 20 mL / min) to obtain the title compound (16 mg, yield: 26.7%, retention time 22.6 minutes; 15 mg, yield: 25.0%, retention time 30.1 minutes).
[0731] Single configuration compound (short retention time)
[0732] MS m / z(ESI):530.2[M+1]
[0733] 1 H NMR (500MHz, DMSO-d6): δ13.41(s,1H),9.85(s,1H),8.34-8.33(m,1H),8.03-7.99(m,1H),7.66-7.62(m,2H),7.44-7.36(m,3H),6.37- 6.35(m,1H),5.15(s,1H),2.26-2.24(m,6H),1.62-1.59(m,1H),1.49(s,3H),0.47-0.45(m,1H),0.28-0.26(m,2H),0.16-0.13(m,1H).
[0734] Single configuration compound (longer retention time)
[0735] MS m / z(ESI):530.2[M+1]
[0736] 1H NMR (500MHz, DMSO-d6): δ13.41(s,1H),9.85(s,1H),8.34-8.33(m,1H),8.03-7.99(m,1H),7.66-7.62(m,2H),7.44-7.36(m,3H),6.37- 6.35(m,1H),5.15(s,1H),2.26-2.24(m,6H),1.62-1.59(m,1H),1.49(s,3H),0.47-0.45(m,1H),0.28-0.26(m,2H),0.16-0.13(m,1H).
[0737] Embodiment 22
[0738] (±)-3-(1-cyclopropyl-1-hydroxyethyl)-4'-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-3-yl)-
[0739] 2-[(1,2'-bipyridyl)-5'-fluoro-2H-[1,2'-bipyridyl]-2-one
[0740]
[0741] Using the synthetic route of Example 21, the first step raw material compound 15a was replaced by 2-bromo-5-fluoro-4-iodopyridine, and the third step raw material compound 7c was replaced by compound 12a to obtain the title compound 22 (15 mg, yield: 32.5%).
[0742] MS m / z(ESI):521.5[M+1]
[0743] 1 H NMR (500MHz, DMSO-d6): δ13.45(s,1H),10.14(s,1H),9.18-9.17(s,1H),8.83-8.82(s,1H),8.38-8.28(m,2H),8.07-8.03(m,1H),7.84-7.82(m, 1H),7.69-7.67(m,1H),6.46-6.43(m,1H),4.97(s,1H),1.70-1.67(m,1H ),1.55(s,3H),0.50-0.48(m,1H),0.29-0.26(m,2H),0.15-0.14(m,1H).
[0744] Embodiment 23
[0745] (±)-3-(1-cyclopropyl-1-hydroxyethyl)-4'-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine
[0746] -3-yl)-5'-methyl-2H-[1,2'-bipyridyl]-2-one 23
[0747]
[0748] first step
[0749] (±)-3-(1-cyclopropyl-1-hydroxyethyl)-4'-iodo-5'-methyl-2H-[1,2'-bipyridyl]-2-one 23a
[0750] Compound 19b (410 mg, 1.37 mmol), 3-(1-cyclopropyl-1-hydroxyethyl)pyridin-2(1H)-one (247 mg, 1.37 mmol, prepared by the method disclosed in intermediate 00242 on page 78 of the specification of patent application WO2023283338A1), cuprous iodide (26 mg, 0.13 mmol, Adamas), N,N'-dimethylethylenediamine (12 mg, 0.13 mmol, Shaoyuan) and potassium carbonate (380 mg, 2.75 mmol, Sinopharm) were placed in 1,4-dioxane (5 mL, Adamas), replaced with nitrogen three times, and stirred at 100°C overnight. 20 mL of water was added to the reaction solution, and the mixture was extracted with ethyl acetate (10 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography with eluent system C to give the title compound 23a (320 mg, yield: 58.6%).
[0751] MS m / z(ESI):397.1[M+1]
[0752] Step 2
[0753] (±)-3-(1-cyclopropyl-1-hydroxyethyl)-5'-methyl-4'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-
[0754] 2H-[1,2'-bipyridyl]-2-one 23b
[0755] Compound 23a (320 mg, 0.81 mmol) was dissolved in 1,4-dioxane (8 mL, Adamas), and bis-pinacol diborane (820 mg, 3.22 mmol, Shaoyuan), potassium acetate (199 mg, 2.02 mmol, Sinopharm), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (60 mg, 0.08 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for overnight reaction. The reaction solution was concentrated, and the residue was purified by column chromatography with eluent system C to obtain the title compound 23b (280 mg, yield: 87.4%).
[0756] MS m / z(ESI):397.2[M+1]
[0757] Step 3
[0758] (±)-3-(1-cyclopropyl-1-hydroxyethyl)-4'-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5'-methyl-2H-[1,2'-bipyridyl]-2-one 23
[0759] Compound 12a (60 mg, 0.16 mmol) was dissolved in 1,4-dioxane (1 mL, Adamas) and water (0.1 mL), and compound 23b (63 mg, 0.16 mmol), cesium carbonate (104 mg, 0.32 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (12 mg, 0.01 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filter, concentrate the filtrate under reduced pressure, and purify the residue by column chromatography with eluent system A to obtain the title compound 23 (2.0 mg, yield: 2.4%).
[0760] MS m / z(ESI):517.2[M+1]
[0761] 1 H NMR (500MHz, DMSO-d6): δ13.85(s,1H),10.08(s,1H),9.15-9.14(m,1H),8. 64-8.62(m,1H),8.37-8.36(m,1H),8.05-8.02(m,2H),7.89-7.87(m,1H),7. 68-7.67(m,1H),6.45-6.43(m,1H),5.04(s,1H),2.52(s,3H),1.68-1.66(m ,1H),1.47(s,3H),0.51-0.48(m,1H),0.30-0.27(m,2H),0.16-0.12(m,1H).
[0762] Embodiment 23-1, 23-2
[0763] (R)-3-(1-cyclopropyl-1-hydroxyethyl)-4'-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5'-methyl-2H-[1,2'-bipyridyl]-2-one 23-1
[0764] (S)-3-(1-cyclopropyl-1-hydroxyethyl)-4'-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5'-methyl-2H-[1,2'-bipyridyl]-2-one 23-2
[0765]
[0766]
[0767] Compound 23 (155 mg, 0.30 mmol) was chirally prepared (separation conditions: chiral preparation column ChiralPak IG, 5 μm, 20 mm*250 mm (Daicel), SN: IG00EJ-CM002; mobile phase: n-hexane: ethanol = 30:70 (v / v), flow rate: 15 mL / min) to give the title compound (34.2 mg, yield: 22.1%, retention time 36.4 minutes; 34.1 mg, yield: 22.0%, retention time 52.5 minutes).
[0768] Single configuration compound (short retention time)
[0769] MS m / z(ESI):517.2[M+1]
[0770] 1 H NMR (500MHz, DMSO-d6): δ13.85(s,1H),10.08(s,1H),9.15-9.14(m,1H),8. 64-8.62(m,1H),8.37-8.36(m,1H),8.05-8.02(m,2H),7.89-7.87(m,1H),7. 68-7.67(m,1H),6.45-6.43(m,1H),5.04(s,1H),2.52(s,3H),1.68-1.66(m ,1H),1.47(s,3H),0.51-0.48(m,1H),0.30-0.27(m,2H),0.16-0.12(m,1H).
[0771] Single configuration compound (longer retention time)
[0772] MS m / z(ESI):517.2[M+1]
[0773] 1 H NMR (500MHz, DMSO-d6): δ13.85(s,1H),10.08(s,1H),9.15-9.14(m,1H),8. 64-8.62(m,1H),8.37-8.36(m,1H),8.05-8.02(m,2H),7.89-7.87(m,1H),7. 68-7.67(m,1H),6.45-6.43(m,1H),5.04(s,1H),2.52(s,3H),1.68-1.66(m ,1H),1.47(s,3H),0.51-0.48(m,1H),0.30-0.27(m,2H),0.16-0.12(m,1H).
[0774] Embodiment 24
[0775] (±)-3-(1-cyclopropyl-1-hydroxyethyl)-4'-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]
[0776] Pyrimidin-3-yl)-5'-methyl-2H-[1,2'-bipyridyl]-2-one 24
[0777]
[0778]
[0779] Step 1 (±)-3-(1-cyclopropyl-1-hydroxyethyl)-4'-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-d]
[0780] Pyrimidin-3-yl)-5'-methyl-2H-[1,2'-bipyridyl]-2-one 24
[0781] Compound 7c (60 mg, 0.15 mmol) was dissolved in 1,4-dioxane (1 mL, Adamas) and water (0.1 mL), and compound 23b (61 mg, 0.15 mmol), cesium carbonate (100 mg, 0.32 mmol, Shaoyuan), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (11 mg, 0.01 mmol, Adamas) were added, and nitrogen was replaced 3 times, and heated to 100°C for 3 hours. Filter, concentrate the filtrate under reduced pressure, and purify the residue by column chromatography with eluent system A to obtain the title compound 24 (2.0 mg, yield: 2.4%).
[0782] MS m / z(ESI):531.2[M+1]
[0783] 1 H NMR (500MHz, DMSO-d6): δ13.41(s,1H),9.85(s,1H),8.34-8.33(m,1H),8.03-7.99(m,1H),7.66-7.62(m,1H),7.44-7.36(m,3H),6.37- 6.35(m,1H),5.15(s,1H),2.26-2.24(m,6H),1.62-1.59(m,1H),1.49(s,3H),0.47-0.45(m,1H),0.28-0.26(m,2H),0.16-0.13(m,1H).
[0784] Embodiment 25
[0785] 4'-(6-((3,5-difluoropyridin-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3-(2-hydroxypropan-2-yl)-5'-
[0786] Methyl-2H-[1,2'-bipyridyl]-2-one 25
[0787]
[0788] The synthetic route of Example 11 was adopted to replace the raw material compound 11b with compound 19d to prepare the title compound 25 (10 mg, yield: 25.3%).
[0789] MS m / z(ESI):490.5[M+1]
[0790] 1 H NMR (500MHz, DMSO-d6): δ13.85(s,1H),9.69(s,1H),8.59(s,1H),8.30-8.29(m,1H),8.16-8.14(m,1H),8.03-8.01(m,1 H),7.99-7.86(m,2H),7.72-7.70(m,1H),7.22-7.20(m,1H),6.45-6.42(m,1H),5.29(s,1H),2.53(s,3H),1.49(s,6H).
[0791] Embodiment 26
[0792] 4'-(6-((3,5-difluoropyridin-2-yl)amino)-4-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-3-(2-hydroxypropane-2-yl)amino)-
[0793] 2H-[1,2'-bipyridyl]-5'-methyl-2H-[1,2'-bipyridyl]-2-one
[0794]
[0795] The synthetic route of Example 11 was adopted, and the raw material compound 11a was replaced with the compound N-(3,5-difluoropyridin-2-yl)-3-iodo-4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridine-6-amine (refer to the synthetic route of 1d in Example 1, and the raw material compound 1a was replaced with the raw material compound 6-chloro-4-methyl-1H-pyrazolo[3,4-b]pyridine (prepared by the method disclosed in step 3 on page 278 of the specification of patent application WO2021134004A1)) to obtain the title compound 26 (4 mg, yield: 12.6%).
[0796] MS m / z(ESI):504.5[M+1]
[0797] 1 H NMR (500MHz, CD3OD): δ8.61(s,1H),8.14-8.13(m,1H),7.82-7.81(m,1H),7.77-7.75(m,2H ),7.65-7.61(m,1H),7.50(s,1H),6.53-6.51(m,1H),2.36-2.35(m,6H),1.60-1.59(m,6H).
[0798] Biological evaluation
[0799] The present disclosure is further described and explained below in conjunction with test examples, but these test examples are not meant to limit the scope of the present disclosure.
[0800] Test Example 1: An endpoint enzymatic experiment based on HTRF technology was used to evaluate the inhibitory activity of the disclosed compounds on the p38alpha-iMK2 kinase cascade reaction.
[0801] 1. Experimental Materials and Instruments
[0802] 1. MAPKAPK2, Inactive protein (Thermo, PV3316)
[0803] 2. MAPK14 (p38 alpha) protein (Thermo, PR5049C)
[0804] 3. HTRF KinEASE-STK S1 kit (Cisbio, 62ST1PEC)
[0805] 4. TritonX-100, polyethylene glycol tert-octylphenyl ether (Sigma, T8787)
[0806] 5. Magnesium chloride (Sigma, 63069)
[0807] 6. ATP, adenosine triphosphate (Promega, V915B)
[0808] 8. DTT, DL-dithiothreitol (Sigma, 43816)
[0809] 7. Microplate reader (BMG LABTECH GmbH, PHERAstar FS)
[0810] 2. Experimental steps
[0811] HTRF KinEASE-STK S1 is a universal method developed by Cisbio for detecting serine / threonine kinase activity based on HTRF technology. In the optimized experimental conditions, 0.05nM iMK2, 0.0015nM activated p38 alpha, biotin-labeled kinase substrate S1 (1μM), ATP (100μM) and different concentrations of compounds were incubated at room temperature for 1 hour. The reaction buffer was HTRF Enzymatic Buffer Kinase in the HTRF KinEASE-STK S1 kit with 10mM MgCl2, 0.01% TritonX-100, and 1mM DTT added. The enzymatic reaction was carried out in a Coring 384 surface low-adhesion microplate with a total reaction volume of 10μL. At the end of the enzymatic reaction, 10μL of streptavidin-labeled XL665 and Eu-labeled STK antibody were added to terminate the enzyme reaction at a final concentration of 62.5nM. After incubation for 1 hour at room temperature, the fluorescence signals at 620 nm and 665 nm were detected using a PHERAstar FS microplate reader under 337 nm wavelength excitation light. The calibrated fluorescence signal was obtained by calculating the ratio of the 665 nm and 620 nm fluorescence signals. The concentration-effect curve of the compound concentration and the enzyme activity inhibition rate was obtained by four-parameter nonlinear fitting using GraphPad PRISM software (Version 9.00; GraphPad San Diego, CA), and the relative IC 50 The values were used to reflect the inhibitory activity of different compounds on the p38alpha-iMK2 cascade reaction.
[0812] Table 1 Inhibitory activity of the disclosed compounds on MK2
[0813]
[0814] Conclusion: The disclosed compounds have a good inhibitory effect on the p38alpha-iMK2 cascade reaction.
[0815] Test Example 2: U937 cytokine secretion experiment based on ELISA technology was used to evaluate the inhibitory activity of the disclosed compounds on the MK2 signaling pathway.
[0816] U937 cells differentiate into macrophages after PMA treatment, and express TLR4 receptors on their surface. When TLR4 is activated by LPS, the secretion of cytokines such as TNF is induced through the downstream p38 / MK2 signaling pathway. After the addition of antagonistic compounds, the above pathway is inhibited, and the secretion of cytokines is reduced. The TNF secretion is measured by Elisa to calculate the IC 50 , thereby evaluating the activity of the compound.
[0817] 1. Experimental Materials and Instruments
[0818] 1. U937 cells (ATCC)
[0819] 2. PMA (InvivoGen, tlrl-pma)
[0820] 3. LPS (Biyuntian, S1732-5mg)
[0821] 4. Human TNF-α ELISA kit, (Xinbosheng, EHC103a.96.10)
[0822] 5. Microplate reader (BMG LABTECH GmbH, PHERAstar FS)
[0823] 2. Experimental steps
[0824] On the first day, U937 cells were planted in culture dishes, and 10 ng / mL PMA was added to RPMI-1640, 10% FBS medium to induce macrophage differentiation, and cultured in a 37°C, 5% CO2 incubator for 48 hours. On the third day, the culture medium was replaced with a medium without PMA and continued to be cultured. On the fourth day, the differentiated cells were scraped with a cell scraper, plated in a 96-well plate with 50,000 cells per well, and cultured overnight. On the fifth day, the cells were treated with different concentrations of compounds for 60 minutes, and then 100 ng / ml LPS was added for treatment for 6 hours. The supernatant was collected and tested for TNF factor by ELISA, and the absorbance at a wavelength of 450 nm was detected using a PHERAstar FS microplate reader. The four-parameter nonlinear fitting of GraphPad PRISM software (Version 9.00; GraphPad San Diego, CA) was used to obtain the concentration-effect curve of compound concentration and TNF secretion inhibition rate, and the relative IC was calculated. 50 The values were used to reflect the activity of different compounds on the secretion of downstream cytokines of the MK2 pathway.
[0825] Table 2 Inhibitory activity of the disclosed compounds on MK2
[0826]
[0827] Conclusion: The disclosed compounds have a good inhibitory effect on the secretion of inflammatory factor TNF by LPS-activated macrophages.
[0828] Test Example 3: Pharmacokinetic Evaluation
[0829] 1. C57 mouse experiment
[0830] 1. Summary
[0831] C57 mice were used as test animals, and the LC / MS / MS method was used to determine the drug concentrations in the plasma of C57 mice at different times after oral gavage (ig) and intravenous injection (iv) of the example compounds, to study the pharmacokinetic behavior of the disclosed compounds in C57 mice and evaluate their pharmacokinetic characteristics.
[0832] 2. Experimental plan
[0833] 2.1. Experimental Drugs
[0834] Compound 7 and Compound 8.
[0835] 2.2 Experimental Animals
[0836] Thirty-six female C57 mice were equally divided into four groups and provided by Weitonglihua Experimental Animal Technology Co., Ltd.
[0837] 2.3 Drug preparation
[0838] A certain amount of the test compound was weighed respectively, and 5% DMSO + 5% Tween 80 + 90% normal saline was added to prepare a 0.1 mg / mL colorless clear solution.
[0839] 2.4 Drug administration
[0840] Intragastric administration group: the dosage was 2.0 mg / kg, and the administration volume was 20 mL / kg.
[0841] Intravenous group: The dosage was 1.0 mg / kg and the administration volume was 10 mL / kg.
[0842] 3. Operation
[0843] In the oral gavage group, 0.1 mL of blood was collected from the eye socket at 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 11.0, and 24.0 hours after administration. The blood was placed in an EDTA-K2 anticoagulant tube and centrifuged at 10,000 rpm for 1 minute (4°C) to separate the plasma. The plasma was separated within 1 hour and stored at -20°C for testing. The blood collection and centrifugation process was operated under ice bath conditions. In the intravenous group, 0.1 ml of blood was collected from the eye socket at 5 minutes, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 11.0, and 24.0 hours after administration, and the treatment was the same as the oral gavage group.
[0844] Determination of the content of the test compound in the plasma of C57 mice after administration of different compounds: Take 50 μL of the plasma sample of C57 mice at each time after administration, add 25 μL of camptothecin (1 μg / mL) and 450 μL of acetonitrile, vortex mix for 5 minutes, and centrifuge at 3700 rpm for 15 minutes. Take 0.2 μL of the supernatant for LC / MS / MS analysis.
[0845] 4. Pharmacokinetic parameter results
[0846] Table 3. Pharmacokinetic parameters of the disclosed compounds in C57 mice
[0847]
[0848] Conclusion: The disclosed compounds have high blood drug concentration, high exposure, and low clearance in C57 mice, and have pharmacokinetic advantages.
[0849] 2. SD rat experiment
[0850] 1. Summary
[0851] SD rats were used as test animals, and the LC / MS / MS method was used to determine the drug concentrations in the plasma at different times after the example compounds were administered to SD rats by gavage (ig) and intravenous injection (iv), to study the pharmacokinetic behavior of the disclosed compounds in SD rats and to evaluate their pharmacokinetic characteristics.
[0852] 2. Experimental plan
[0853] 2.1. Experimental Drugs
[0854] Compound 7.
[0855] 2.2 Experimental Animals
[0856] Eight SD rats, half male and half female, were equally divided into two groups (provided by Weitonglihua Experimental Animal Technology Co., Ltd.), and were administered drugs by gavage and intravenous injection after fasting overnight.
[0857] 2.3 Drug preparation
[0858] A certain amount of the test compound was weighed respectively, and 5% DMSO + 5% Tween 80 + 90% normal saline was added to prepare a 0.2 mg / mL colorless clear solution.
[0859] 2.4 Drug administration
[0860] Intragastric administration group: the dosage was 2.0 mg / kg, and the administration volume was 10 mL / kg.
[0861] Intravenous administration group: the dosage was 1.0 mg / kg and the administration volume was 5 mL / kg.
[0862] 3. Operation
[0863] In the intravenous administration group, 0.2 mL of blood was collected from the eye socket at 5 minutes, 0.25 hours, 0.5 hours, 1.0 hours, 2.0 hours, 4.0 hours, 8.0 hours, 11.0 hours, and 24.0 hours after administration. The blood was placed in an EDTA anticoagulant tube and centrifuged at 10,000 rpm for 2 minutes (4°C) to separate the plasma, which was then stored on dry ice or at -80°C for testing. Plasma was separated within 1 hour, and the blood collection and centrifugation process was performed under ice bath conditions within 1 hour. Food and water intake was resumed 2 hours after administration.
[0864] In the oral administration group, 0.2 mL of blood was collected from the eye socket at 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 11.0, and 24.0 h after administration and the blood was treated in the same way as the intravenous administration group.
[0865] Determination of the content of the test compound in the plasma of SD rats after administration of different compounds: 50 μL of SD rat plasma samples at each time after administration were added with 25 μL camptothecin (1 μg / mL) and 450 μL acetonitrile, vortexed for 5 minutes, and centrifuged at 3700 rpm for 10 minutes. 0.2 μL of the supernatant was taken for LC / MS / MS analysis.
[0866] 4. Pharmacokinetic parameter results
[0867] Table 4. Pharmacokinetic parameters of the disclosed compounds in SD rats
[0868]
[0869] Conclusion: The disclosed compounds have high blood drug concentration, high exposure, and low clearance in SD rats, and have pharmacokinetic advantages.
Claims
1. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof: in: Ring A is a heteroaryl group; Ring B is phenyl or monocyclic heteroaryl; Ring C is selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; X is N or CR 5 ; Y is N or CR 6 ; Z is N or CR 7 ; R 0 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, a hydroxyalkyl group, an alkoxyalkyl group, an aminoalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group; Each R 1 , R 2 and R 3 are the same or different and are each independently selected from a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, a hydroxyalkyl group, an alkoxyalkyl group, an aminoalkyl group, an alkoxy group, a haloalkoxy group, a deuterated alkoxy group, an alkenyl group, an alkynyl group, a cyano group, a nitro group, a hydroxyl group, an amino group, an oxo group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, a heteroarylalkyl group, a -(CH 2 ) t OR 8 、-(CH 2 ) t NR 9 R 10 、-C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-OC(O)OR 8 、-C(O)NR 9 R 10 、-OC(O)NR 9 R 10 、-S(O) v R 8 、-S(O) v NR 9 R 10 、-NR 11 C(O)NR 9 R 10 、-NR 11 C(O)R 8 and-NR 11 C(O)OR 8 wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R A replace; R 4 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, a hydroxyalkyl group, an alkoxyalkyl group, an aminoalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group; R 5 , R 6 and R 7 are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, a hydroxyalkyl group, an alkoxyalkyl group, an aminoalkyl group, an alkoxy group, a haloalkoxy group, a deuterated alkoxy group, an alkenyl group, an alkynyl group, a cyano group, a nitro group, a hydroxyl group, an amino group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, a heteroarylalkyl group, a -(CH 2 ) t OR 8 、-(CH 2 ) t NR 9 R 10 、-C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-OC(O)OR 8 、-C(O)NR 9 R 10 、-OC(O)NR 9 R 10 、-S(O) v R 8 、-S(O) v NR 9 R 10 、-NR 11 C(O)NR 9 R 10 、-NR 11 C(O)R 8 and-NR 11 C(O)OR 8 wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R A replace; R A are the same or different at each occurrence and are each independently selected from the group consisting of a deuterium atom, a halogen, an alkyl, a haloalkyl, a deuterated alkyl, a hydroxyalkyl, an alkoxyalkyl, an aminoalkyl, an alkoxy, a haloalkoxy, a deuterated alkoxy, an alkenyl, an alkynyl, a cyano group, a nitro group, a hydroxyl group, an amino, a cycloalkyl, a heterocyclyl, a cycloalkylalkyl, a heterocyclylalkyl, an aryl, a heteroaryl, an arylalkyl, a heteroarylalkyl, an oxo group, a -(CH 2 ) t OR 12 、-(CH 2 ) t NR 13 R 14 、-C(O)R 12 、-C(O)OR 12 and -C(O)NR 13 R 14 ; R 8 and R 12 are the same or different at each occurrence and are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, deuterated alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl; wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl is independently optionally replaced by one or more R B replace; R 9 , R 10 , R 11 , R 13 and R 14 are the same or different at each occurrence and are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, deuterated alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl; wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl is independently optionally replaced by one or more R B replace; or R 9 and R 10 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R B Replace; or R 13 and R 14 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R B replace; R B is the same or different at each occurrence and is independently selected from a deuterium atom, a halogen, an alkyl, a haloalkyl, a deuterated alkyl, a hydroxyalkyl, an alkoxyalkyl, an aminoalkyl, an alkoxy, a haloalkoxy, a deuterated alkoxy, an alkenyl, an alkynyl, a cyano group, a nitro group, a hydroxyl group, an amino group, -NHCH 3 、-N(CH 3 ) 2 , cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy, heterocyclyloxy, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aryloxy, heteroaryloxy, and oxo; m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3, 4 or 5; p is 0, 1, 2, 3, 4 or 5; t is 0, 1, 2, 3 or 4; and v is 0, 1, or 2.
2. The compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, which is a compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof: in: Ring A, Ring B, Ring C, Y, Z, R 1 , R 2 , R 3 , m, n and p are as defined in claim 1.
3. The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein ring A is a 6-membered heteroaryl group; preferably, ring A is a pyridyl group.
4. The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein ring B is phenyl or a 5- or 6-membered heteroaryl group; preferably, ring B is phenyl or pyridyl.
5. The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein ring C is a 5- or 6-membered heteroaryl group; preferably, ring C is a pyrimidinyl group or a pyridone group.
6. The compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, which is a compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof: in: Q is N or CR 2d ; E is N or CR 3d ; R 1a , R 1b , R 1c and R 1d are the same or different and are each independently a hydrogen atom or R 1 ; R 2a , R 2b , R 2c and R 2d are the same or different and are each independently a hydrogen atom or R 2 ; R 3a , R 3b , R 3c and R 3d are the same or different and are each independently a hydrogen atom or R 3 ; Y, Z, R 1 , R 2 and R 3 As defined in claim 1.
7. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, wherein each R 1 The same or different, and each independently is a halogen; preferably, each R 1 are the same or different and are each independently F or Cl.
8. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein each R 2 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Alkoxy; preferably, R 2 It is methyl.
9. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, wherein each R 3 The same or different, and each independently selected from C 1-6 Alkyl, C 2-6 alkenyl and 3 to 8 membered cycloalkyl; said C 1-6 Alkyl, C 2-6 The alkenyl group and the 3 to 8 membered cycloalkyl group are each independently optionally selected from C 1-6 alkyl, hydroxyl and 3 to 6-membered cycloalkyl; preferably, each R 3 The same or different, and each independently is C 1-6 More preferably, R 3 for 10. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 6 to 9, wherein R 1a is halogen; R 1b is a hydrogen atom; R 1c is a hydrogen atom or a halogen; R 1d A hydrogen atom.
11. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 6 to 10, wherein Q is N or CH; and / or R 2b Selected from halogen, C 1-6 Alkyl and C 1-6 Alkoxy; and / or R 2a is a hydrogen atom or a halogen; and / or R 2c is a hydrogen atom; Preferably, Q is CH; and / or R 2b C 1-6 Alkyl; R 2a and R 2c is a hydrogen atom; More preferably, Q is CH; and / or R 2b is methyl; R 2a and R 2c A hydrogen atom.
12. The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 6 to 11, wherein E is N; and / or R 3a Selected from C 1-6 Alkyl, C 2-6 alkenyl and 3 to 8 membered cycloalkyl; said C 1-6 Alkyl, C 2-6 The alkenyl group and the 3 to 8 membered cycloalkyl group are each independently optionally selected from C 1-6 alkyl, hydroxyl and 3 to 6-membered cycloalkyl; and / or R 3b is a hydrogen atom; and / or R 3c is a hydrogen atom; Preferably, E is N; and / or R 3a C 1-6 Hydroxyalkyl; R 3b and R 3c is a hydrogen atom; More preferably, E is N; and / or R 3a for R 3b and R 3c A hydrogen atom.
13. A compound represented by general formula (I) according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein Y is N, Z is CR 7 ; or Y is CR 6 , Z is N; or, Y is CR 6 , Z is CR 7 ; R 6 and R 7 As defined in claim 1; preferably, Y is N and Z is CH.
14. A compound represented by general formula (I) according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof, which is selected from any one of the following compounds:
15. A compound represented by the general formula (IA) or a salt thereof: in: PG is an amino protecting group; preferably, PG is SEM or THP; Ring A, Ring B, Ring C, X, Y, Z, R 0 , R 1 , R 2 , R 3 , m, n and p are as defined in claim 1.
16. The compound represented by the general formula (IA) or a salt thereof according to claim 15, which is selected from any one of the following compounds:
17. A method for preparing the compound represented by general formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, the method comprising: include: Removing the protecting group from the compound represented by the general formula (IA) or its salt to obtain the compound represented by the general formula (I) or its pharmaceutically acceptable salt; in: PG is an amino protecting group; preferably, PG is SEM or THP; R 4 is a hydrogen atom; Ring A, Ring B, Ring C, X, Y, Z, R 0 , R 1 , R 2 , R 3 , m, n and p are as defined in claim 1.
18. A pharmaceutical composition comprising a compound represented by general formula (I) according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
19. Use of the compound represented by general formula (I) according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 18 in the preparation of an MK2 inhibitor.
20. Use of a compound of formula (I) according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to claim 18 in the preparation of a medicament for treating and / or preventing autoimmune disorders, chronic or acute inflammatory disorders, autoinflammatory disorders, fibrotic disorders, metabolic disorders, neoplasia and cardiovascular or cerebrovascular disorders; the autoimmune disorders, chronic or acute inflammatory disorders and autoinflammatory disorders are preferably selected from inflammatory bowel disease, ulcerative colitis, psoriasis, Crohn's disease (CD), multiple sclerosis, psoriasis, arthritis, ankylosing spondylitis, asthma, chronic obstructive pulmonary disease (COPD), cryopyri-associated periodic syndrome, Muckle-Wells syndrome (Muckle-Wells syndrome) syndrome), familial cold autoinflammatory syndrome, neonatal onset multisystem inflammatory disease, TNF receptor-associated periodic syndrome, acute and chronic pancreatitis, atherosclerosis, gout, acute respiratory distress syndrome, autoimmune hemolytic syndrome, autoimmune and inflammatory hepatitis, autoimmune neuropathy, autoimmune ovarian failure, autoimmune orchitis, autoimmune thrombocytopenia, systemic lupus erythematosus, vasculitis syndrome, hypophysitis, idiopathic platelet Purpura, pemphigus, autoimmune deafness, meningitis, myocarditis, gingivitis, enterocolitis, sinusitis, uveitis, ophthalmitis, optic neuritis, gastric ulcer, esophagitis, peritonitis, root periostitis, dermatomyositis, gastritis, myositis, bronchitis, novel coronavirus infection (COVID-19) and suppurative hidradenitis; the arthritis is preferably selected from rheumatoid arthritis (RA), psoriatic arthritis, osteoarthritis, juvenile arthritis, psoriatic arthritis, reactive arthritis and spondyloarthritis.
Citation Information
Patent Citations
P38 MAPK / MK2 pathway regulator and composition, preparation method and application thereof
CN116354935A
Substituted pyridinone-pyridinyl compounds
WO2012078684A1
Substituted pyrimidinone-phenyl-pyrimidinyl compounds
WO2013086208A1
N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
WO2014140065A1
Methyl / fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
WO2014197846A1
